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ABSTRACT 
The pituitary gonadotropes synthesize and secrete luteinizing hormone (LH) and follicle-
stimulating hormone (FSH), which control reproductive development and function. In 
mature gonadotropes and in the LβT2 cell line, both hormones are regulated by GnRH, 
but the hormone-specific β subunits are not expressed in the αT3-1 cells, which represent 
an immature gonadotrope. In order to identify novel factors and mechanisms involved in 
basal and GnRH-induced gonadotropin gene transcription, subtractive hybridization was 
carried out to reveal genes expressed in mature LβT2 but not in immature αT3-1 cells, or 
those whose expression in LβT2 cells is induced following GnRH treatment. A number 
of candidate genes was identified, among them the ubiquitin-conjugating enzyme 4 
(ubc4), and calmodulin-dependent serine/threonine protein phosphatase calcineurin, both 
of which are up-regulated following GnRH treatment. Functional studies revealed that 
GnRH increases estrogen receptor α (ERα) degradation and transactivation of the LHβ 
gene in LβT2 cells, apparently through stimulation of ubc4 expression. It was further 
demonstrated that the stimulatory effect of ERα on LHβ expression is mediated through 
interactions with other regulatory transcription factors Pitx1 and Sf-1 on the proximal 
promoter, without necessarily requiring an ERE. Calcineurin is activated by GnRH and 
regulates both basal and GnRH stimulated human αGSU promoter activity, through its 
target NFAT proteins. NFAT4, which is not affected by GnRH treatment, is 
constitutively associated with the human αGSU promoter and mediates the promoter 
basal activity, while NFAT3, activated by GnRH through calcineurin, is associated with 
the human αGSU promoter only after GnRH treatment and may mediate the GnRH effect 
on the human αGSU promoter. Furthermore, calcineurin plays a role in the GnRH-
mediated derepression of the FSHβ gene in the immature gonadotrope αT3-1 cells, 
possibly by activating its targets MEF2D and Nur77. Nur77 expression is induced by 
GnRH, which is calcineurin-dependent. Both of the two factors are associated with the 
FSHβ gene promoter and activate FSHβ gene transcription or promoter activity when 
over-expressed. It was further demonstrated that GnRH-activated CaMKI is also required 
for GnRH to overcome the histone deacetylase (HDAC)-mediated repression of the FSHβ 
gene.  
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CHAPTER 1   INTRODUCTION 
 
1.1 Gonadotropins  
 
1.1.1 Physiology of the gonadotropins 
The pituitary, a small gland located beneath the hypothalamus, rests in a depression of the 
skull base called the sella turcica. It synthesizes and secretes polypeptide hormones 
essential for growth, reproduction, metabolic regulation, environmental adaptations and 
other biological activities. The pituitary consists of three sections: the anterior lobe, the 
intermediate lobe and the posterior lobe. The anterior pituitary contains five hormone-
secreting cell types. One of these, the gonadotrope, synthesizes and secretes two distinct 
gonadotropins: luteinizing hormone (LH) and follicle-stimulating hormone (FSH; 
Jacobson et al., 1979; Fig 1.1) 
 
1.1.2 Genomic organization of the gonadotropins 
The gonadotropins LH and FSH belong to the glycoprotein hormone family, which also 
includes thyroid-stimulating hormone (TSH) and chorionic gonadotropins (CG; Pierce 
and Parsons, 1981). Both LH and FSH are heterodimeric hormones, sharing a common 
αGSU, while possessing a hormone specific β subunit, which defines its biological 
activity and physiological specificity (Chin and Gharib, 1986; Gharib et al., 1990). The 
common α and specific β subunit genes are localized on different chromosomes. 
Synthesis of biologically active LH and FSH requires the coordinated transcription and 
noncovalent assembly of the two subunits.  





















Fig 1.1:  Anatomical and functional connections of the hypothalamic-pituitary axis.  
(A) The pituitary is a small, bean-shaped gland that sits below the brain in a well-protected position. (B) 
Embryologically, anatomically and functionally, the pituitary gland is divided into posterior and anterior 
lobes. The latter consists of a collection of endocrine cells: somatotrope, lactotrope, corticotrope, 
gonadotrope and thyrotrope. They synthesize and secrete growth hormone (GH); prolactin (PRL); 
adrenocorticotropic hormone (ACTH); luteinizing and follicle-stimulating hormone (LH and FSH); and 
thyroid-stimulating hormone (TSH), respectively. Nerve cells in the hypothalamus secrete neurohormones 
that, via a system of hypophyseal portal vessels, act on the endocrine cells to stimulate or inhibit their 
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1.1.3 Biological functions of the gonadotropins  
LH and FSH bind to their specific receptors in the gonad to initiate sexual maturation and 
maintain cyclical reproductive function (Backstrom et al., 1982). In the testis, LH acts on 
the Leydig cells to stimulate synthesis and secretion of steroid hormones, especially the 
production of androgens (Dufau, 1988), while FSH acts on the Sertoli cells to stimulate 
production of sperm (Tapanainen et al., 1997). In the ovary, FSH stimulates maturation 
of ovarian follicles and conversion of androgens to estrogens (Aittomaki et al., 1996; 
Kumar et al., 1997), while LH promotes maturation of follicular cells. After the initial 
LH receptor (LHR) expression in the small follicles, LH enhances the subsequent stages 
of follicular development in granulosa and luteal cells (Richards and Hedin, 1988). The 
preovulatory LH surge triggers ovulation of mature follicles by promoting the rupture of 
the follicle and the release of the ovum. In addition, LH also leads to the synthesis and 
subsequent release of progesterone by the corpus luteum (Norris, 1997).   
 
1.1.4 Murine αT3-1 and LβT2 gonadotrope cell lines  
Much of the recent research on the regulation of gonadotropin genes and GnRH signaling 
has been carried out using the αT3-1 or LβT2 cell lines, which were generated by 
targeted oncogenesis in transgenic mice (Alarid et al., 1996; Turgeon et al., 1996; Windle 
et al., 1990). The αT3-1 cell line represents an early gonadotrope that is not fully 
differentiated and expresses the pituitary glycoprotein αGSU, GnRH receptor (GnRHr) 
and transcription factors steroidogenic factor 1 (Sf-1), pituitary homeobox-1 (Pitx1 or 
Ptx1), and early growth response factor-1 (Egr-1), but does not express either the LHβ or 
the FSHβ gene (Horn et al., 1991; Windle et al., 1990). The LβT2 cell line represents a 
mature gonadotrope that is fully differentiated, expressing the GnRH receptor, Sf-1, Pitx1, 
  4  
Egr-1, both α and LHβ subunits, and LHβ transcription increases in response to GnRH 
treatment (Turgeon et al., 1996). Although these cells were originally thought to lack 
expression of FSHβ, recent studies have shown that LβT2 cells do express FSHβ, and 
support the basal and stimulated FSHβ promoter activity by GnRH and activin (Graham 
et al., 1999; Pernasetti et al., 2001; Fig 1.2). Although the transcription factors known to 
be essential for LHβ expression are present in both cell lines, LHβ is only expressed in 
LβT2 cells (Alarid et al., 1996; Windle et al., 1990). Therefore, the two cell lines provide 
useful comparative model systems to investigate FSHβ and LHβ transcriptional 




Fig 1.2: A diagrammatic representation of the gonadotrope cell lineage development in the mouse. 
The initiation of anterior pituitary differentiation is marked by the expression of the glycoprotein hormone 
α subunit gene. The emergence of mature gonadotropes occurs in two stages, with the expression of LHβ 
and FSHβ subunit genes on E16.5 and E17.5, respectively. These temporal and distinct stages of 
differentiation were captured by target oncogenesis in transgenic mice to generate immortalized immature 
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1.2 Molecular regulation of gonadotropin synthesis and secretion  
The differential synthesis and secretion of gonadotropins are regulated by a number of 
factors along the hypothalamus-pituitary-gonadal axis, including gonadotropin-releasing 
hormone (GnRH), steroid hormones (estrogen, androgen and progesterone) and gonadal 
peptides (activin and inhibin; Gharib et al., 1990; Landefeld et al., 1983; Ling et al., 1986; 
Papavasiliou et al., 1986; Fig 1.3). The main regulator of gonadotropins is GnRH, which 
is secreted from the hypothalamus in a pulsatile manner to stimulate LH and FSH 
expression. GnRH differentially regulates each of the gonadotropin subunit genes 
expression through its delivery at the gonadotrope in pulses of different frequency and 
amplitude (Dalkin et al., 1989; Haisenleder et al., 1991; Haisenleder et al., 1988; Kirk et 
al., 1994). Furthermore, use of GnRH antagonist to block or suppress GnRH actions, 
diminishes LH and FSH levels, which leads to failure of sperm production or cessation of 
female reproductive cycles (Shupnik, 1990; Shupnik and Fallest, 1994). Gonadal steroids 
and peptides act at the hypothalamus to alter GnRH pulsatility and also directly on the 
pituitary to either positively or negatively regulate LH and FSH synthesis and secretion 


























Fig 1.3: Overview of the regulation of gonadotropins in the hypothalamic-pituitary-gonadal axis. 
GnRH, which is secreted from the hypothalamus, binds to the GnRH receptors on the surface of the 
gonadotrope. GnRH acts on the gonadotrope to stimulate the synthesis and secretion of LH and FSH, which 
stimulate the production of steroid hormones: testosterone, estrogen and progesterone by the gonads. These 
hormones negatively or positively regulate the synthesis of the gonadotropins directly at the pituitary or 
indirectly at the hypothalamus by modulating GnRH secretion. The gonadal peptides: inhibin, activin and 
follistatin (FS) also have roles in the regulation of gonadotropin gene expression by exerting positive or 


























                 Gonadal Peptides 
Inhibin (-ve), Activin (+ve), FS (-ve) 
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1.2.1 Transcriptional regulation of gonadotropin subunits 
Transcriptional regulation of gonadotropin subunit genes is mainly achieved by a series 
of temporally and spatially expressed transcription factors that are recruited to the 
promoters of these genes (Treier et al., 1998). The intrinsic interactions between these 
factors or with their specific co-activator complexes initiate and maintain the temporal 
and cell-specific expression of gonadotropin genes during the embryonic development. 
Initially in the gonadotrope cell lineage, the αGSU transcript is expressed at 
approximately embryonic day 11.5 (e11.5) in the mouse, and after a further 5 or 6 days, 
LHβ and FSHβ are expressed on e16.5 and e17.5, respectively (Japon et al., 1994).  
 
1.2.1.1 Transcriptional regulation of the αGSU  
The common subunit of the glycoprotein hormones, the αGSU, is expressed in three cell 
types: gonadotrope, thyrotrope, and trophoblast. The cell-specific expression of this 
subunit gene is regulated by distinct sets of cis-acting elements (Hamernik et al., 1992). 
In the gonadotrope, more than 15 regulatory elements on the human or mouse αGSU 
promoter are reported to define the promoter activity (Fig 1.4). Among these binding 
sites, the cAMP response elements (CREs) and the pituitary glycoprotein hormone basal 
element (PGBE; Schoderbek et al., 1992) in the 5’ regulatory region are critical for the 
αGSU basal promoter activity. Electrophoretic mobility shift analysis (EMSA) and 
supershift analysis showed that the CREs could bind different transcription factors, 
including CRE binding protein (CREB), activating transcription factors (ATF) 1 and 2, 
and c-jun (Drust et al., 1991; Heckert et al., 1995; Heckert et al., 1996). A more recent 
report using DNA pull-down assays identified that activating transcription factor 3 
  8  
(ATF3), a transcription factor induced by GnRH, activates the human αGSU promoter 
activity by binding the CRE site (Xie et al., 2005). EMSA and screening a mouse cDNA 
library revealed that the PGBE binds a LIM-homeodomain transcription factor, LH-2 
(Brinkmeier et al., 1998; Roberson et al., 1994). However, PGBE is also bound and 
transactivated by P-LIM/Lhx3 (Bach et al., 1995). Use of human αGSU promoter 
mutants identified that α-basal element 1 and 2 (αBE1 and 2) are also necessary for the 
basal αGSU promoter activity, and these elements were shown to be human specific. 
EMSA demonstrated that two factors, designated as αBP1 and αBP2, bind the αBE 
region. Southwestern blotting indicated that αBP1 is a heterodimeric protein with the 
possible sizes of 54 and 56-KDa, while the attempts to identify αBP2 were unsuccessful 
(Heckert et al., 1995). For the mouse αGSU promoter, a specific enhancer region 
between -4.6 and -3.7 kb critical for high level expression of αGSU subunit in both 
gonadotrope and thyrotrope cells was identified. Transfection studies demonstrated that 
the enhancer stimulated the -341/+43 mouse αGSU promoter activity in the αT3-1 cells 
(Brinkmeier et al., 1998). 
 
There are also some other weak elements that provide minor contributions to the αGSU 
promoter activity, including Sf-1 binding site gonadotrope-specific element (GSE), 
GATA2 binding site (αACT), and AP-2 binding site trophoblast-specific element (TSE; 
Harris et al., 2003; Johnson et al., 1997b; Steger et al., 1994). In addition, Pitx1 knockout 
resulted in suppression of both P-LIM and αGSU gene expression, suggesting that Pitx-1 
may also activate αGSU gene expression (Sheng et al., 1996; Tremblay et al., 1998).  
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Additional studies have shown that the GnRH-responsive element (GnRH-RE) in the 
human αGSU promoter is located at -346 to -244 bp, corresponding to the PGBE, αBE 
and a putative Ets binding element (Kay and Jameson, 1992; Maurer et al., 1999; 
Roberson et al., 1995). Recently, the GSE and upstream regulatory element (URE) 
sequences (-180 to -156 bp) were also found to be implicated in a minor role for GnRH 
responsiveness (Fowkes et al., 2002; Harris et al., 2003). It was concluded that the 
GnRH-responsive region PGBE and αBE and the tandem CREs affect each other’s 
activities, which suggests that precise control of basal and GnRH stimulated αGSU gene 
expression is not regulated by a single element, but rather by intrinsic interplay between 
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Fig 1.4: Several elements define the αGSU expression.  
(A) Specific promoter elements along with their cognate binding factors are responsible for α gene 
expression. Human and rodent sequences are similar but have unique properties that define both basal and 
GnRH-responsive expression. Elements that bind shaded factors contribute to gonadotrope-specific 
expression and include the E boxes, Pitx1 binding element, CRE, αACT, GSE, αBE1 and -2 (human 
specific), PGBE, GnRH-RE, and distal enhancer sequences (both murine specific). (B) The human αGSU 
promoter depends on synergistic participation from factors that bind the tandem CREs, αBE1 and αBE2, 
and PGBE. These studies imply that the factors that bind these elements interact with each other, 
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1.2.1.2 Transcriptional regulation of the LHβ and FSHβ subunits 
In a fashion similar to the αGSU promoter, the LHβ gene is also regulated by a 
combinatorial array of transcription factors and regulatory elements on the promoter. The 
proximal 140 bp region in the mammalian LHβ promoter containing Pitx1, Sf-1 and  
Egr-1 binding site is highly conserved across all species studied so far. The three binding 
sites are found to be functional and act synergistically to mediate the promoter basal or 
GnRH-stimulated activity (Dorn et al., 1999; Halvorson et al., 1999; Quirk et al., 2001; 
Tremblay and Drouin, 1999). Sf-1 is an orphan nuclear receptor found  in the 
gonadotropes of the anterior pituitary and also in other non-pituitary steroidogenic tissues 
including the adrenal glands, gonads, placenta, and the ventromedial nucleus of the 
hypothalamus (Ikeda et al., 1993; Ikeda et al., 1995; Luo et al., 1994). In the Sf-1 
knockout mice, both αGSU and LHβ subunit expression were significantly decreased 
(Shinoda et al., 1995). Pitx1 is expressed in several anterior pituitary cell lineages and 
transactivates most of the anterior pituitary cell-specific genes, including gonadotropin α, 
FSHβ and LHβ genes (Tremblay et al., 1998). In the Pitx1 null mice, the number of cells 
expressing LHβ decreased (Szeto et al., 1999; Tremblay et al., 1999). Egr-1 is a zinc 
finger transcription factor that binds to a GC-rich sequence in DNA to activate gene 
transcription. Targeted disruption of Egr-1 resulted in the selective loss of LH synthesis 
and secretion (Lee et al., 1996; Topilko et al., 1998). Different from Sf-1 and Pitx1 
whose protein levels are not affected by GnRH, Egr-1 protein levels are barely detectable 
in unstimulated cells, but increase significantly within 30 min GnRH exposure (Dorn et 
al., 1999; Halvorson et al., 1999; Tremblay and Drouin, 1999). Such induction of Egr-1 
occurs through GnRH activation of the protein kinase C (PKC) and mitogen-activating 
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protein kinase (MAPK) pathways (Dorn et al., 1999; Wolfe, 1999; Khokhlatchev et al., 
1998).  
In contrast to the proximal promoter, the sequence of the mammalian LHβ promoter 
upstream of the 140 bp region is not well conserved across the species. Sp1 and CArG 
binding sites have been identified in the distal domain of the rat LHβ  promoter sequence, 
while in the bovine promoter, the corresponding region contains a nuclear transcription 
factor-Y (NFY) binding site (Kaiser et al., 1998a; Kaiser et al., 1998b; Weck et al., 2000). 
The identified Sp1 region in the rat LHβ promoter plays an important role in conferring 
GnRH responsiveness: mutations of the Sp1 binding sites, which blocks binding of Sp1, 
decreased the stimulation of the rat LHβ gene promoter by GnRH, while the role for NFY 
in mediating GnRH effect has not been established (Jorgensen et al., 2004; Kaiser et al., 
2000; Kaiser et al., 1998a; Keri et al., 2000). The roles for Sp1 and other factors binding 
the distal elements of the LHβ gene promoter in activation of LHβ are not confirmed. The 
suggested mechanism is that these factors may interact with the proximal promoter 
binding proteins through a co-activator complex. One possible such co-activator is the 
small nuclear ring finger protein (SNURF), which associates with the LHβ promoter and 
interacts with both Sf-1 and Sp1. Over-expression of SNURF increased both basal and 
GnRH stimulated LHβ gene expression (Curtin et al., 2004).    
Compared to LHβ, regulation of the FSHβ subunit gene at the molecular level is less well 
understood. A number of studies have revealed there are conserved activator protein-1 c-
jun and c-fos (AP-1 factor) response elements in the FSHβ proximal promoter region 
(Cesnjaj et al., 1994; Liu et al., 2002a; Strahl et al., 1998). However, these conserved 
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AP-1 elements seem not to mediate GnRH stimulatory effects on the FSHβ subunit in the 
gonadotrope cells (Huang et al., 2001; Vasilyev et al., 2002). Recent studies revealed that 
a novel half AP-1 binding site, adjacent to a binding site for NFY, is present in the mouse 
FSHβ promoter, but not in ovine and bovine FSHβ promoters. The composite AP-1/NFY 
binding site is required for AP-1 binding and is critical for full activation of FSHβ by 
GnRH (Coss et al., 2004). In addition, two Sf-1 response elements were identified on the 
FSHβ promoter, which interact with the NFY response element to regulate FSHβ gene 
expression. Moreover, physical interaction between Sf-1 and NFY was also confirmed 
(Jacobs et al., 2003). The LIM-homeodomain transcription factor P-LIM was shown to 
regulate the basal FSHβ gene expression, however, whether P-LIM mediates GnRH 
effects on FSHβ still remains to be elucidated (West et al., 2004). Pitx-1 activation of the 
rat FSHβ (rFSHβ) promoter activity through both direct and indirect interactions with the 
rFSHβ gene promoter in LβT2 cells has been reported (Zakaria et al., 2002). Considering 
that P-LIM interacts with the C-terminal region of Pitx1 to activate αGSU gene promoter 
activity (Bach et al., 1997), the indirect effects of Pitx1 on FSHβ may be through 
interactions with P-LIM, but this possibility needs to be confirmed. Furthermore, Pitx2, 
another member of the Pitx subfamily, is also required for FSHβ expression (Suszko et 
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1.2.2 GnRH induced signaling pathways in stimulation of gonadotropin gene 
expression  
The action of GnRH is mediated through binding a G-protein coupled seven-
transmembrane receptor, which is bound to two specific GTP-binding proteins (Gq, G11) 
(Hsieh and Martin, 1992; Liu et al., 2002b; Reinhart et al., 1992). GnRH receptor 
(GnRHr) activation induces activation of phospholipase C (PLC) and an increase in 
intracellular cAMP levels (Bourne, 1988; Hsieh and Martin, 1992). The elevated cAMP 
levels activate the downstream cAMP dependant kinase (PKA; Lippmann, 1975; Yoshida 
et al., 1975), while PLC accelerates the cleavage of phosphatidylinositol 4,5-
bisphosphate (PIP2), thereby stimulating production of 1, 4, 5-triphosphate (IP3) and 
diacylglycerol (DAG; Andrews and Conn, 1986). IP3 induces the calcium release from 
the intracellular stores, and also extracellular calcium influx through voltage-sensitive L-
type calcium channels (Naor, 1990). DAG activates protein kinase C (PKC), which 
activates the downstream mitogen-activated protein kinase (MAPK) pathways, including 
extracellular signal regulated kinase (ERK), c-jun NH2-terminal kinase (JNK), and p38 













Fig 1.5: Signal transduction pathways activated by GnRH.  
GnRH activates a number of signaling pathways, including MEK, JNK, ERK1/2, cAMP/PKA, PKC, Ca2+ 
and CaM-dependent pathways. A number of transcription factors are activated through phosphorylation by 




















      Gonadotropins (LHβ, FSHβ, α) 
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1.2.2.1 Calcium  
The roles for GnRH-induced Ca2+ signals in mediating gonadotropin subunit gene 
expression and secretion have been extensively studied (Mulvaney et al., 1999; Naor, 
1990; Naor et al., 1998; Stojilkovic and Catt, 1995). However, due to differences in cell 
models tested, or the final product measured, controversial results were observed. In rat 
pituitary cells, the rapid stimulatory effect of GnRH on αGSU and LHβ mRNA levels, 
but not FSHβ, was abolished in Ca2+-free medium (Ben-Menahem and Naor, 1994). In 
αT3-1 cells, promoter studies combined treatment with L-channel antagonist (nimodipine) 
and specific inhibitor of MEK (PD098059) revealed that GnRH induction of rat LHβ 
promoter is dependent on calcium influx, while induction of rat αGSU promoter by 
GnRH was dependent on MAPK pathway and not affected by elimination of intra- or 
extracellular calcium (Weck et al., 1998). However, another report using a 
somatolactotrope cell line GH3 that was stably transfected with the GnRH receptor, 
indicated that PKC-dependent pathways stimulate rat LHβ and FSHβ promoters to a 
larger extent than the human aGSU promoter, while calcium influx has a larger 
stimulatory effect on the human αGSU promoter than rat LHβ or FSHβ promoter 
(Saunders et al., 1998).   
 
Calcium is an important mediator in the activation of downstream intracellular second 
messengers, including PKC, JNK and ERK (Johnson et al., 1997a; Mulvaney and 
Roberson, 2000; Reiss et al., 1997). However, the specific downstream factors mediating 
these calcium effects in GnRH signaling pathway have yet to be fully characterized. It 
has been reported that in both rat primary pituitary cells and LβT2 cells, GnRH stimulates 
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calcium/calmodulin (CaM) dependent kinase II (CaMKII) phosphorylation and activation 
(Haisenleder et al., 2003a; Haisenleder et al., 2003b). Treatment with CaMK inhibitor, 
KN-93, decreased the GnRH induction of the rat αGSU and LHβ promoter activity and 
GnRH-stimulated αGSU, LHβ, and FSHβ mRNA levels (Haisenleder et al., 2003a; 
Haisenleder et al., 2003b). More recently, studies in αT3-1 cells revealed that inhibition 
of CaM using W7 blocks GnRH-induced ERK, as well as ERK-dependent gene reporter 
activity of c-fos, murine αGSU and MAPK phosphatase (MKP)-2 promoters (Roberson 
et al., 2005). However, in that study, the CaMK inhibitor KN62 did not recapitulate these 
findings, which suggested that other CaM-dependent signaling mediators also are 
involved in mediating the GnRH effects (Roberson et al., 2005). 
 
1.2.2.2 PKC/MAPK pathway 
Compared to the calcium pathway, findings on PKC regulation of gonadotropin genes are 
more consistent: studies agree that PKC is involved in the GnRH stimulation of αGSU, 
LHβ and FSHβ gene expression (Andrews et al., 1988; Halvorson et al., 1999; Kay et al., 
1994; Schoderbek et al., 1993; Strahl et al., 1998). In the rat primary pituitary cells, the 
rapid stimulatory effect of GnRH on all three gonadotropin subunit mRNA levels was 
abolished by the PKC inhibitors, staurosporine and GF 109203X (Ben-Menahem et al., 
1994). For PKC stimulation of LHβ, one of the identified mechanisms is that PKC 
phosphorylates and activates the transcription factor Egr-1, which binds and activates the 
LHβ promoter in synergy with Sf-1 and Pitx1 (Halvorson et al., 1999; Kaiser et al., 2000; 
Tremblay and Drouin, 1999). In addition, PKC phosphorylates and activates Sp-1, which 
mediates GnRH effects on the LHβ promoter (Kaiser et al., 1998a). The mechanism for 
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PKC activation of the FSHβ promoter activity may involve AP-1 activation and binding 
(Strahl et al., 1998).  
 
In the GnRH signaling, MAPK-dependent activation of αGSU subunit (Roberson et al., 
1995), GnRH receptor (White et al., 1999), c-fos, and c-jun genes have been reported 
(Cesnjaj et al., 1993; Levi et al., 1998; Mulvaney and Roberson, 2000; Mulvaney et al., 
1999). The mechanism for MAPK-dependent activation of αGSU subunit in αT3-1 cells 
has been suggested to involve MAPK-activated Ets factor binding and activation 
(Roberson et al., 1995). Cotransfection with either dominant negative JNK or dominant 
negative c-jun significantly inhibited the induction of the rat LHβ promoter by GnRH, 
which suggests that the JNK cascade is necessary to elicit the rat LHβ promoter activity 
in a c-jun-dependent mechanism (Yokoi et al., 2000). P38 also activates the AP-1 
transcription factor (Roberson et al., 1999), and one recent report revealed that p38 is 
involved in GnRH stimulation of the bovine FSHβ promoter activity, but the mechanism 
needs to be confirmed (Bonfil et al., 2004). 
 
1.2.2.3 cAMP/PKA pathway  
GnRH activates the cAMP/PKA pathway, which has been shown to activate the mouse, 
rat and human αGSU promoter activity (Attardi and Winters, 1998; Maurer et al., 1999). 
In rat pituitary cells, a cAMP analogue increased  αGSU mRNA levels, but not those of 
LHβ and FSHβ (Haisenleder et al., 1992). The crosstalk between the cAMP/PKA 
pathway and other intracellular signaling pathways (PKC and ERK) in mediating GnRH 
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effects has been reported, but the mechanisms remain elusive (Garrel et al., 1997; Han 
and Conn, 1999). 
 
In summary, GnRH-stimulated gonadotropin gene expression involves activation of 
different signal transduction pathways and their downstream transcription factors, which 





(A) Basal Gene Expression                            (B) GnRH-stimulated Gene Expression 
Fig 1.6: Schematic model of basal and GnRH-stimulated gonadotropin subunit gene expression.  
(A). Transcription factors involved in basal gonadotropin subunit gene expression are activated during 
anterior pituitary development and are shown bound to their cognate DNA elements in the gonadotropin 
subunit gene promoters. (B). The GnRH-regulated transcription factors, shown together with their putative 
second messenger signaling pathways. Interactions between basal and GnRH-regulated transcription factors 
are as follows: Sf-1 synergises with Egr-1 (Halvorson et al., 1998; Lee et al., 1996); LH-2 synergises with 
Ets (Roberson et al., 1994); GnRH regulates SP-1 (Kaiser et al., 1998a), Egr-1 (Halvorson et al., 1999), Ets 
Roberson et al., 1995) and AP-1 (Strahl et al., 1998). Extracellular Ca2+ influx upregulates unknown factor 
x, which transactivates α and LHβ promoters (Holdstock et al., 1996; Weck et al., 1998). Abbreviations are 
given in the text. Adapted from Brown and McNeilly, 1999. 
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1.2.3 Gonadal peptide-mediated regulation of FSHβ gene expression 
Inhibin, activin and follistatin (FS) are produced in both gonads and the pituitary gland, 
and changes in their relative concentrations alter FSH expression levels (Carroll et al., 
1989; Mather et al., 1997). A member of the transforming growth factor β (TGFβ) 
superfamily, activin stimulates FSH synthesis and release from pituitary cell cultures 
(Ling et al., 1986; Vale et al., 1986), while inhibin acts to suppress pituitary FSH 
transcription and secretion (Burger and Robertson, 1997; Burger et al., 2001; Haisenleder 
et al., 1990). Activin binds to its type II receptor subunit on the cell surface, which then 
pairs with a type I receptor subunit. The serine/threonine kinase activity of the type II 
subunit phosphorylates the associated type I subunit, which initiates post-receptor 
signaling/phosphorylation. The identified activin downstream pathway involves the 
mothers against dpp-related (Smad) proteins (reviewed in Derynck and Zhang, 2003). 
Smad2 and 3 are phosphorylated by activin receptor activation and interact with Smad4, 
which then binds to DNA to regulate the target gene activity. In the pituitary cells, 
activin-induced FSHβ is associated with the increased phosphorylation of Smad2 and 3, 
and over-expression of Smad3 increased mouse or rat FSHβ promoter activity (Bernard, 
2004; Dupont et al., 2003). Inhibin also binds the activin type II receptor, but with much 
lower affinity than activin, and this binding does not promote phosphorylation of the type 
I receptor, so producing an antagonistic effect through preventing the stimulatory actions 
of activin (Attisano and Wrana, 1996; DePaolo, 1997). Follistatin (FS) is a glycoprotein 
structurally unrelated to the activins and inhibins. Due to its high binding affinity to 
activin, FS binds to and neutralizes the bioactivity of activin on the FSHβ subunit (Burger 
et al., 2002; Nakamura et al., 1990).  
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1.2.4 Estrogen (E2)-mediated regulation of LHβ gene expression  
One of the most central roles for E2 is regulating the production of gonadotropins in the 
pituitary gland, which is exerted via negative and positive feedback acting at the brain 
and pituitary. It is the high level of estradiol (E2) at the end of the follicular phase that 
works synergistically with GnRH and leads to the pre-ovulatory LH surge that initiates 
ovulation.  
 
Despite evidence that E2 enhances LHβ gene transcription directly, the molecular 
mechanisms involved have remained elusive (Brown and McNeilly, 1999; Gharib et al., 
1990; Keri and Neilson, 1994). Since most of the biological functions of E2 are 
transduced by ER, it is possible that E2, through ER binding to the estrogen response 
element (ERE) on the LHβ gene promoter, activates gene expression. However, among 
all the mammalian LHβ promoters studied, only the rat LHβ gene contains a possible 
ERE. This element, located 1159 bp upstream of the transcriptional start site, was shown 
to bind recombinant ER in gel shift assays (Shupnik and Rosenzweig, 1991), but bears 
little resemblance to the consensus ERE motif and is not found on the homologous genes 
of other mammals. Thus any direct actions of the liganded ER on the LHβ gene promoter, 
if they occur, are likely to involve other DNA binding factors, as shown for example for 
Sp1 and AP-1. This contrasts with the situation in teleost fish in which all of the isolated 
LHβ gene proximal promoters do contain a near-consensus ERE, and in Chinook salmon 
this was shown to mediate estrogen/ERα responsiveness (Fig 1.7). Moreover, Sf-1 and 
ER were shown to interact synergistically to increase the Chinook salmon LHβ (csLHβ) 
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promoter activity (Drean et al., 1996; Liu et al., 1995). This synergistic action was 















Figure 1.7: Disparity between the binding sites on the LHβ gene proximal promoters of teleosts and 
mammals.  
A comparison of the promoter sequence of LHβ gene in Chinook salmon, common carp, goldfish and a 
typical mammalian LHβ gene was carried out. The conserved Egr-1 binding site on the mammalian 
promoter is lacking in those of the teleosts. Instead, a near consensus palindromic ERE is found together 
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To date, two estrogen receptors ERα and ERβ have been identified in the mouse 
(Tremblay et al., 1997). In ERα knockout mice, both sexes are characterized with 
immature reproductive organs and infertility, which suggest that ERα has a key role in 
the reproductive development and function (Lubahn et al., 1993; Muramatsu and Inoue, 
2000). As a member of nuclear receptor superfamily, ERα shares the common functional 
domains named A to F with other nuclear receptors. The N-terminal A/B region contains 
an autonomous activation function (AF-1). The conserved C domain is the DNA-binding 
domain, which consists of two zinc-finger-like motifs. The D domain is a variable hinge. 
The multifunctional C-terminal (domain E) is the ligand-dependent domain (LBD), a 
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Fig 1.8: Genomic organization and functional domains of murine ERα.  
ER has two major transactivation functions (AF), AF-1 (domain B) and AF-2 (domain E and F), which 
generate surfaces that bind to cofactors which in turn recruit the transcriptional machinery and transactivate 
gene transcription. ER binds to the EREs on the target gene promoter via its DNA binding domain (DBD; 
domain C), which contains two zinc finger motifs. Domain D is the hinge region and domain E is the 
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Unliganded ERα is predominantly located in the nucleus and is found as a monomer or as 
dimers (Aumais et al., 1997; Nathan et al., 1997). Upon ligand binding, ERα undergoes a 
major conformation change that stabilizes the ERα dimer. Typically, ERα associates with 
the promoter of E2-responsive genes on specific sequences termed estrogen responsive 
elements (EREs). ERα activation of a target gene involves recruitment of transcription 
cofactor complexes, which include p160/SRC-1 family members, CBP/P300, and 
DRIP/TRAP co-activator complex (Cavailles et al., 1994; Cavailles et al., 1995; 
Halachmi et al., 1994; Onate et al., 1995; Rachez et al., 1999).  
Studies have shown that administration of E2 downregulates the ERα steady-state levels, 
through decreasing the protein half-life. As with other proteins, which have a rapid 
turnover, ERα ligand-dependent degradation appears to involve ubiquitylation which 
signals proteasome-mediated degradation (Alarid et al., 1999). Degradation of a protein 
via the ubiquitin-proteasome pathway involves two discrete and successive steps: 
covalent attachment of poly-ubiquitin chains to the lysine residue of target proteins 
(conjugation), which requires the sequential ATP-dependent actions by E1 (ubiquitin-
activating), E2 (ubiquitin-conjugating) and E3 (ubiquitin ligase) enzymes; and the 
subsequent degradation of the tagged protein by the 26S proteasome (composed of the 
catalytic 20S core and the 19S regulator; Passmore and Barford, 2004; Fig 1.9). Recently, 
a direct correlation between the rate of ERα degradation and its transcriptional activity 
has been noted (Lonard et al., 2000; Reid et al., 2003; Wijayaratne, 2001). However, how 
these two seemingly opposing observations can be reconciled is not yet clear.  
 
 


































Fig 1.9: The ubiquitin-proteasome pathway.  
Ubiquitin (Ub) is covalently attached to substrate proteins via a three-step mechanism involving the 
sequential actions of E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme) and E3 
(ubiquitin ligase) enzymes. The attachment of multiple ubiquitin moieties by E3, perhaps with the help of 
an E4, results in formation of a poly-ubiquitin chain. Poly-ubiquitylated proteins are recognized and 





  26  
1.3 High throughput approaches for study of gene expression 
In higher eukaryotes, biological processes such as cell growth, organogenesis and bodily 
functions are mediated by programs of differential gene expression. In order to examine 
the mechanisms regulating these processes, a variety of functional genomics approaches 
have been developed and utilized to examine the relevant subsets of differentially 
expressed genes. These include, for example, differential display (DD; Liang and Pardee, 
1992), serial analysis of gene expression (SAGE, Velculescu et al., 1995), 
cDNA/oligonucleotide microarrays (Schena et al., 1995) and subtractive cDNA 
hybridization (Welcher et al., 1986), 
 
Differential display (DD) allows visualization and comparison of the differential 
expression profiles from two or more samples. Typical DD involves multiple steps: 
reverse transcription of total RNA with either an arbitrary primer or an oligo(dT) primer, 
then PCR amplification with an arbitrary primer or an arbitrary primer paired with an 
oligo(dT) primer to amplify the cDNA, finally separation and identification of the 
differential PCR products (Liang and Pardee, 1992; Matz and Lukyanov, 1998). DD is 
useful when investigating low or medium-abundance novel genes (Bertioli et al., 1995), 
however, the differences in abundant transcripts may not be detected by DD (Matz and 
Lukyanov, 1998). Furthermore, previous studies showed that the false positives 
percentage is very high using this technique, which maybe due to reverse transcription 
and PCR artifacts (Stein and Liang, 2002). In addition, DD is not suitable for use in 
experiments in which only a few genes are expected to vary (Sompayrac et al., 1995). 
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SAGE is designed to detect and quantify the expression of large numbers of known and 
unknown transcripts (Velculescu, 1999; Velculescu et al., 1995). Two major steps are 
involved in this method. First, several short cDNA tags (10-14 bp) are concatemerized 
and cloned into a vector for sequencing. Second, each clone produces around 35 tags, 
which are used to identify corresponding genes; the frequency that each gene occurs is 
used to determine the gene’s expression levels (Velculescu et al., 1995). SAGE technique 
has been utilized to provide global transcription profiles of well-characterized organisms 
(Velculescu, 1999; Velculescu et al., 1995) or specific cell types or tissue with low 
cellular diversity (Stollberg et al., 2000). However, it is troublesome to clone all the 
different kinds of expressed sequence tags (EST) in SAGE. In addition, SAGE could 
result in a significant underestimation of the number of active genes in the fraction of 
genes expressed at low copy number. Also, unique SAGE tags may be caused by a 
sequencing error, so not all unique SAGE tags are present in the cDNA population 
(Stollberg et al., 2000). 
 
DNA microarray analysis is a recently developed molecular biotechnology tool, which 
allows simultaneous analysis of thousands of genes. Typical microarray analysis consists 
of a regular microscope glass slide that contains thousands of microscopic quantities of 
PCR products of cDNA or synthetic oligonuclotides of genes (Kehoe et al., 1999; Schena 
et al., 1995). The major advantage of microarray technology is that it can be used to 
investigate global transcription patterns quickly owing to the fact that many genes can be 
analyzed at one time (Lievens et al., 2001). However, due to the cloning, genome 
sequencing and microarray equipment costs, DNA microarrays are very expensive to 
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manufacture. Another limiting factor is that a large amount of poly-A RNA is needed for 
each microarray, which poses a particular problem when investigating systems in which 
tissue or cells exist only in small quantities. Microarray is also not good to look for novel 
genes, as it is limited by what has been put on the microarray slide, so it is biased by that 
which is already known. Microarray also does not have the capacity to differentiate 
alternate splicing of a gene (Kehoe et al., 1999; Knight, 2001).  
  
Subtractive hybridization has been shown to be an efficient approach to study differences 
in DNA or cDNA abundance in both eukaryotes and prokaryotes (Duguid and Dinauer, 
1990; Hara et al., 1991). Different from microarray, it can identify previously 
uncharacterized genes (novel genes), and a low rate of false positive is achieved by using 
this method (Duguid and Dinauer, 1990). A variation of this is suppression subtractive 
hybridization (SSH; Diatchenko et al., 1996), which is based on selective amplification 
of differentially expressed sequences; this can overcome many technical limitations of 
the traditional subtraction methods (Diatchenko et al., 1996). Traditional subtractive 
hybridization requires more than 20 µg of initial poly A+ RNA, and involves several 
rounds of hybridization (Hubank and Schatz, 1994). For SSH, only 0.5-2 µg of poly A+ 
mRNA is required. In addition, rare messages are not easily identifiable in traditional 
subtraction methods, while SSH prevents undesirable amplification, so the high, middle, 
low, or rare-abundance target molecules can be cloned with equal probability (Duguid 
and Dinauer, 1990; Hedrick et al., 1984; Sargent and Dawid, 1983). However, as in other 
approaches, the differential expression of the identified genes by SSH also need to be 
verified by northern blotting, RNA slot blotting, RNase protection assay, or RT-PCR. 
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The principle of SSH is shown in Fig 1.10. In brief, two different mRNA populations are 
first converted into cDNA: the cDNA that contains specific (differentially expressed) 
transcripts is designated as the tester, and the reference cDNA as the driver. Tester and 
driver cDNAs are then hybridized, and the hybrid sequences removed. Consequently, the 
remaining unhybridized cDNAs representing genes that are expressed in the tester yet 
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Fig 1.10: Overview of the BD PCR-Select subtractive hybridization method.  
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1.4 Hypothesis and aims 
 
1.4.1 Hypothesis  
Gonadotropin subunit gene expression, at a basal level and in response to GnRH, requires 
the activation of a number of specific transcription factors, only some of which have been 
identified to date. It is hypothesized that genes differentially expressed in LβT2 and αT3-
1 cells are responsible for the basal LHβ gene expression, and that GnRH up- or down-
regulates specific genes to transduce its stimulatory effects to the gonadotropins. 
Utilization of subtractive hybridization, a high throughput genomic approach, would 
allow identification of these differentially expressed or GnRH-regulated genes, and lead 
to the discovery of novel factors regulating gonadotropin gene expression.   
 
1.4.2 Aims  
The purpose of this study was to discover novel genes and pathways that are involved in 
regulating basal and GnRH-stimulated gonadotropin expression through use of 
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CHAPTER 2           MATERIALS AND METHODS 
 
2.1 Cell culture 
 
2.1.1 Medium and culture conditions  
The αT3-1 cells (a gift from Dr. P. Mellon, San Diego) were cultured in Modified Eagle 
Medium (MEM) supplemented with 10 % fetal bovine serum (FBS), 10 mM HEPES (pH 
7.5), 0.1 mM MEM non-essential amino acids, 1 mM sodium pyruvate solution and 100 
µg/mL penicillin (Gibco-Invitrogen) and 100 µg/mL streptomycin (Gibco-Invitrogen). 
The COS 1 cell line, a mammalian kidney cell line, was cultured as the αT3-1 cells. LβT2 
cells (also a gift from Dr. P. Mellon) were cultured in Dulbeco’s Modified Eagle’s 
medium (DMEM) containing 4.5 g/L glucose supplemented with 10 % certified FBS, 10 
mM HEPES ( pH 7.5), 100 µg/mL penicillin and 100 µg/mL streptomycin (Gibco-
Invitrogen). All cells were maintained at 37 °C under 5 % CO2. 
 
2.1.2 Storing of cells 
The cells were rinsed once with 1×HBSS, trypsin was added together with the cell-
specific medium to collect the cells to a 1.5 mL cryogenic microfuge tube (NUNC). The 
tube was centrifuged at 2000 rpm for 2 min. The supernatant was discarded. The pellet 
was resuspended with freezing solution (90 % cell specific media and 10 % DMSO). The 
tubes of cells were then incubated at -80 oC overnight before storing them in a liquid 
nitrogen storage tank. 
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2.1.3 Recovery of cells 
The tube of frozen cells was placed in ice to thaw. The cells were then directly poured 
into a 100 mm culture dish containing 10 mL of cell-specific medium. The dish was 
incubated at 37 °C under 5 % CO2 for 24 h before the cells were rinsed once with 1X 
HBSS and new medium was added.  
 
2.1.4 Transient transfection of cells 
Transfection was carried out 24 h after cells were plated. COS1 cells were transfected 
using FUGENETM 6 (Roche), αT3-1 and LβT2 cells were transfected using 
GenePORTER 2 (Gene Therapy Systems) Transfection Reagent. The optimized 
transfection Reagent (µL): DNA (µg) ratio is shown in Table 2.1 and 2.2.  
 
Cell type Fugene 6 : DNA ratio 
COS 1 1:1 
Table 2.1: Optimized Fugene 6 Reagent (µL): DNA ratio (µg). 
 
Cell type GenePORTER 2 : DNA ratio 
LβT2 7:2 
αT3-1 5:1 
                            Table 2.2: Optimized GenePORTER 2 Reagent (µL): DNA ratio (µg). 
 
FuGENE6 reagent was added directly into serum-free media to make up the total 
transfection volume to 100 µL for each well of the 6-well plate. The contents were mixed 
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and incubated for 5 min at room temperature (RT). Plasmid DNA was added and the tube 
was gently tapped to mix the contents. It was then incubated for 15 min at RT. The 
mixture was added drop wise to each well of the 6-well plate. The cells were then 
incubated for another 48 h at 37 oC under 5 % CO2 before harvest. 
 
The hydrated GenePORTER 2 reagent was first diluted with serum-free medium, and the 
DNA was diluted with the DNA diluent, and both were incubated for 1 to 5 min at RT, 
after which the DNA solution was added to the diluted GenePORTER 2 reagent and 
incubated at RT for 10 min before it was added to the cells.  
 
2.1.5 Chemical treatment of cells 
αT3-1 and LβT2 cells were exposed to 100 nM GnRH ([D-Ala6]-LHRH; Sigma; 
dissolved in H2O), 10 nM 17 β-Estradiol (E2; Sigma; dissolved in 100 % ethanol), 5 µM 
MG132 (Sigma, dissolved in DMSO), 100 nM PMA (Sigma, dissolved in DMSO), 1 µM 
ionomycin (Io; Sigma, dissolved in DMSO) and 5 µM cyclosporine A (CsA; Sigma; 
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2.2 Plasmid construction  
 
2.2.1 Site-directed mutagenesis of promoters 
The mutants of the csLHβ promoter in CAT3 vector (Xiong et al., 1994), the rLHβ 
promoter in CAT6 vector (Le Dr閍n et al., 1997) and the human αGSU promoter in 
pGL2 basic vector (Heckert et al., 1995) were created using the QuickChangeTM Site-
Directed Mutagenesis Kit (Stratagene). Site-directed mutagenesis PCR reactions were 




DNA template (50 ng) 1 
Forward primer (125 ng) 1 
Reverse primer (125 ng) 1 
10X Pfu Turbo polymerase buffer 5 
dNTP (10 mM) 1 
Sterile distilled water 40 
Pfu Turbo (2.5 U/µL; Stratagene) 1 
Total volume 50 
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Segment Cycle 
Temperature (oC) Time 
1 1 95 30 s 






2 1 16 ∞ 
   Table 2.4: Site-directed mutagenesis PCR cycling parameters (* extension time: 1min/kb 
of plasmid length for plasmid < 6kb in size, 2 min /kb of plasmid length for plasmid > 6 
kb).  
 
Subsequently, 1 µL of the Dpn I restriction enzyme (10 U/µL) was added to each 
amplification reaction. The reaction was then incubated at 37 °C for 1 h to allow 
digestion of the parental (nonmutated) dsDNA before the amplified mutated plasmids 
were transformed. 
 
On the csLHβ proximal promoter, the ERE and proximal Pitx1 RE sites (at -260 bp and  
-232bp; csLHβ ∆ERE-CAT and csLHβ ∆Pitx1-CAT) were deleted and the Sf-1 RE was 
mutated (at -154 bp; csLHβ ∆Sf-1-CAT). The transcription factor binding sites mutated 
on the rLHβ promoter were as follows: proximal Sf-1 (at -51bp; rLHβ ∆pSf-1-CAT) was 
deleted; distal Sf-1 (at -119 bp; rLHβ ∆dSf-1-CAT) was mutated, distal non-consensus 
ERE (at -1159 bp; rLHβ ∆ERE-CAT) was mutated, Pitx-1 (at -93bp; rLHβ ∆Pitx1-CAT) 
was deleted. On the human αGSU promoter, the NFAT binding sites (at -418bp, -390bp, 
-362bp and -300bp; α-Mut1, α-Mut2, α-Mut3 and α-Mut4, respectively) were mutated. 
The specific primers used to create these mutants are shown in Table 2.5. 





Primers Primer sequence (5’-3’) 
csLHβ ∆ERE F GCAGGGATCTAACTCTATGACAATTA(tgtcaatctgacc)C
TATAAAGCCATCAACTCTTGAGGG 
csLHβ ∆ERE csLHβ 
csLHβ ∆ERE R CCCTCAAGAGTTGATGGCTTTATAG(ggtcagattgaca)TA
ATTGTCATAGAGTTAGATCCCTGC 
csLHβ ∆Sf-1 F CTGTGCAAAGTAGACAGCAGGAGGAAGTCATTGTG 
csLHβ ∆Sf-1 csLHβ 
csLHβ ∆Sf-1 R CACAATGACTTCCTCCTGCTGTCTACTTTGCACAG 
csLHβ ∆ERE F GCAGGGATCTAACTCTATGACAATT(tgtcaatctgacc) 
ACTATAAAGCCATCAACTCTTGAGGG csLHβ ∆ERE 
∆Sf-1  
csLHβ 
∆Sf-1 csLHβ ∆ERE R CCCTCAAGAGTTGATGGCTTTATAG(ggtcagattgaca) 
TAATTGTCATAGAGTTAGATCCCTGC 
csLHβ ∆pitx-1F GCCATCAACTCTTGAGG(tta)GTGTCGAATGAATTAAT csLHβ 
∆pitx-1 
csLHβ  
csLHβ ∆pitx-1R ATTAATTCATTCGACAC(taa)CCTCAAGAGTTGATGGC 




∆ERE csLHβ ∆pitx-1R ATTAATTCATTCGACAC(taa)CCTCAAGAGTTGATGGC 




∆Sf-1 csLHβ ∆pitx-1R ATTAATTCATTCGACAC(taa)CCTCAAGAGTTGATGGC 
rLHβ ∆dSf-1 F CTTGGTCCTTTCTGTGCACGTCTGTCTCGCCCCCA 
rLHβ ∆dSf-1 rLHβ 
rLHβ ∆dSf-1 R TGGGGGCGAGACAGCGTGCACAGAAAGGACCAAG 
rLHβ ∆pSf-1 F GTAGCCTCTGCTTAG(tggccttg)CCACCCCCACAACCC rLHβ ∆pSf-1 
∆dSf-1 
rLHβ 
∆dSf-1 rLHβ ∆pSf-1 R GGGTTGTGGGGGTGG(caaggcca)CTAAGCAGAGGCTAC 
rLHβ ∆ERE F GCTTAGTGGCCTTGCTGTCAATCTGACCAACCCGCAGGTATA
AAG 
rLHβ ∆ERE rLHβ 
rLHβ ∆ERE R CTTTATACCTGCGGGTTGGTCAGATTGACAGCAAGGCCACTA
AGC 
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rLHβ ∆pitx-1F TCTCGCCCCCAAAGAGA(tta)GTGTCTAGGTTACCCAG rLHβ ∆pitx-
1 
rLHβ  














Table 2.5: The primers used for site-directed mutagenesis of csLHβ, rLHβ and human αGSU 
promoters.  





2.2.2 Construction of  expression vectors  
The expression vectors for Pitx1, Sf-1 and hERα were gifts from J. Drouin (Montreal), K. 
Parker (Durham, NC) and F. Pakdel (Rennes, France), respectively. The dominant 
negative NFAT (dnNFAT) were kind gifts from Dr C. Chow (New York). The dnNFAT 
construct contains the NFAT NH2-terminal PxIxIT motif, which region is responsible for 
NFAT interaction with calcineurin. When over-expressed, it downregulates NFAT-
dependent transactivation mediated by endogenous or recombinant NFAT proteins 
(Chow et al., 1999). Ubc4 full length cDNA was amplified from LβT2 total cDNA and 
cloned into pCS2 expression vector (Table 2.6). MEF2A, MEF2D, Nur77 and calcineurin 
catalytic subunit A (CnA) full length cDNA were amplified from αT3-1 total cDNA and 
cloned into pCS2 expression vector (Table 2.6). The constitutively active CnA (CA-CnA) 
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expression vector was constructed by deletion of CaM-binding domain and autoinhibitory 





Restriction site Expression 
vector 
























NM_010444 BamHI, EcoRI pCS2 
gcagaattctcagaaagacaatgtgtcc 
Table 2.6: The primers used for construction of expression vectors. 
 
 
2.2.3 Construction of siRNA constructs  
 
2.2.3.1  Oligonucleotide design 
Oligonucleotides were designed based on the mRNA sequence, using the design tools 
from Oligoengine (http://www.oligoengine.com). Pairs of oligos were synthesized to 
target ERα, ubc4 and CnA as shown in Table 2.7 




Sequence (5’-3’) Forward  













             Table 2.7: Oligonucleotides designed for synthesis of siRNA.  
             Gene specific sequences are underlined. 
 
 
2.2.3.2  Annealing of oligos 
The oligos were dissolved in sterile, nuclease-free H2O to a concentration of 3 µg/µL and 
the annealing reactions were assembled in a 50 µL reaction by mixing 1 µL of each oligo 
with 48 µL annealing buffer (100 mM NaCl and 50 mM HEPES pH 7.4). Annealing was 
carried out under the conditions shown in Table 2.8. 
 
Conditions  Time  
90 °C 4 min 
70 °C 10 min 
Step wise cooling to 4 °C 2 h 
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2.2.3.3 Restriction digestion of vectors 
The modified pSUPER vector (1 µg, Oligoengine) was linearized with Hind III (1 µL; 10 
U/µL; Promega) for 1 h, after which Bgl II (1 µL; 10 U/µL; Promega) was added for 
another 2 h in a total reaction volume of 20 µL. Both digestions were carried out at 37 °C. 
Enzymes were then inactivated at 65 °C for 15 min. 
 
2.2.3.4 Extraction of DNA from gel 
The digested DNA was run on a 1 % agarose gel and the linearized vector was excised 
and purified from the gel using Gel purification kit (Qiagen) according to the 
manufacturer’s instructions. 
 
2.2.3.5 Ligation of annealed oligos and linearized pSUPER vector 
Ligation mixure was assembled as shown in Table 2.9 and ligation with the vector was 
carried out 2 h at RT. A negative control without insert was carried out in parallel. After 
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Components Volume 
(µL) 
Annealed oligos 1 
Linearized pSUPER vector (0.3 µg/µL) 1 
T4 DNA ligase buffer 10X (Promega) 1 
T4 DNA ligase (3 U/µL, Promega) 1 
Sterile distilled water 6 
Total volume 10 
              Table 2.9: Ligation reaction mix. 
 
 
2.2.4 Constructs for mammalian two-hybrid assay 
The ERα cDNA was cloned into the Gal4 DNA binding domain (DBD) encoding plasmid 
(pM), and the ERα, Sf-1, and Pitx1 cDNAs were cloned into the activation domain-
encoding plasmid (pVP16; both from Clontech). The pM and pVP expression vectors 










































Table 2.10: The primers used for construction of pM and pVP constructs. 
 
2.3  Isolation, verification and maxiprep of plasmids 
 
2.3.1 Transformation of plasmids into Escherichia coli (E.coli) cells 
A single colony of E.coli DH5α was added to 5 mL of Luria-Bertani (LB) medium, and 
incubated for 16 h at 37 oC, 250 rpm before transferring to 200 mL of LB medium and 
incubation under the same conditions until the OD600 reached a value of 0.3 to 0.6. The 
bacterial culture was then centrifuged at 1700 × g for 15 min at 4 oC. The pellet was 
resuspended on ice in 1/20 volume filtered TSS [LB broth (pH 6.1), 10 % polyethylglycol 
(Sigma), 5 % dimethylsulfoxide (Sigma), 10 mM MgCl2 and 10 mM MgSO4 at final pH 
6.5-6.8]. The competent cells were stored in aliquots of 200 µL at -80 oC.  
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Thawed competent E.coli DH5α cells (100 µL) were transformed with the desired 
plasmid DNA together with 100 µL of KCM (100 mM KCl, 30 mM CaCl2 and 50 mM 
MgCl2). The mixture was then incubated on ice for 1 h before plating on LB-Ampicillin 
agar plates and incubation overnight at 37 oC. 
 
2.3.2 Plasmid isolation and verification  
Plasmid DNA of selected colonies was extracted using Wizard Plus SV Miniprep Kit 
(Promega) according to manufacturer’s instructions. Automated sequencing (ABI 
Prism® 3100) was carried out to verify all the mutated plasmids, expression vectors and 
siRNA constructs obtained. The primers used are shown in Table 2.11. Sequencing PCR 
reactions were assembled as shown in Table 2.12. Cycling parameters are shown in Table 
2.13. 
 
Target plasmids Sequence (5’-3’) 
pSUPER vector gtaatacgactcactatagggcga 
CAT 3  gcttaacatcaaaacacgtcct 
CAT 6 proximal tccctaccttgggcacttgg 
CAT 6 distal gagcattcatcaggcgggcaag 
pGL2 basic tgtatcttatggtaactgtaactg 
pCS2  taatacgactcactataggg 
pM tcatcggaagagagtagtaa 
pVP gccgacttcgagtttgagca 
     Table 2.11: Primers used for sequencing reactions. 






Components Volume (µL) 
Big dye version 3 (Applied Biosystems) 2 
Primer (5 pM/µL) 1 
DNA template (250-500 ng) 1 
5x sequencing buffer (Applied Biosystems) 2 
Sterile distilled water 4 
Total volume 10 
                  Table 2.12: Sequencing reaction mix.  
 
Segment Cycle 
Temperature (oC) Time 






2 1 16 ∞ 
   Table 2.13: Sequencing PCR parameters. 
 
The amplified DNA was precipitated on ice for 10 min with 20 µL of 3 M NaOAc (pH 
4.6) and 50 µL 95% ethanol followed by centrifugation at 20800 × g for 30 min at RT to 
pellet the DNA. The pellet was washed twice with 70 % ethanol and dried before 
carrying out automated sequencing on the ABI Prism® 3100 (Perkin Elmer). 
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2.3.3 Large-scale plasmid DNA isolation and purification 
After verifying the results from sequencing, the selected colony was grown in 500 mL 
conical flask containing 250 mL LB, and the specific antibiotics (100 µg/mL). The 
culture was shaken in a 37 oC incubator set at 250 rpm for about 16 h. The Quantum Prep 
plasmid maxiprep kit (BIO-RAD) was used to isolate the plasmid DNA. 
 
2.4 RT-PCR analysis 
 
2.4.1 RNA isolation 
RNA was isolated from the cells using Trizol® reagent (Invitrogen) according to the 
manufacturer’s instructions.  
 
2.4.2 First strand cDNA synthesis 
First strand cDNA was synthesized from the RNA isolated. Oligo dT (NEB) was 
annealed to the poly A-tail of mRNA in the reaction shown in Table 2.14 by heating the 
mixture to 65 oC for 5 min and chilling quickly on ice. 
Components Volume (µL) 
Oligo (dT) 12-18 (500 µg/mL, New England Biolabs)  1 
RNA (5 µg) 5 
10 mM dNTP mix   1 
Sterile distilled nuclease free water 5 
Total volume 12 
Table 2.14: Reaction mix for annealing oligo dT to isolated mRNA. 
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Subsequently, to the mix was added the 4 µL of 5× First strand buffer (Invitrogen) and 2 
µL of 0.1 M DTT, and this was incubated at 42 oC for 2 min before addition of 1 µL of 
Superscript Reverse Transcriptase (Invitrogen). The mix was then incubated at 42 oC for 
80 min before heat inactivation at 70 oC for 15 min. 
 
2.4.3 PCR and gel electrophoresis analysis 
PCR reactions using primers to amplify the mouse LHβ, FSHβ, calcineurin A, Nur77, 
MEF2 and NFAT cDNA, with β-actin gene as internal control were carried out as shown 
in Table 2.15 with the cycling parameters in Table 2.16. The primers used are listed in 




Dynazyme buffer 10X (Finnzyme) 2.5 
Forward primer (25 µM) 1 
Reverse primer (25 µM) 1 
cDNA template  2 
10 mM dNTPs 0.5 
Sterile distilled water 17.5 
Dynazyme (2 U/µL, Finnzyme) 0.5 
Total volume 25 
                      Table 2.15: PCR mix to analyze gene expression levels by RT-PCR. 
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Segment Cycle 
Temperature (oC) Time 
1 1 95 5 min 






3 1 72 5 min 
4 1 16 ∞ 
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LHβ gene F GCCTGTCAACGCAACTCTGG 20 
LHβ gene R CAGGCCATTGGTTGAGTCCT 20 
298 
FSHβ gene F AGCACTGACTGCACCGTGAG 20 
FSHβ gene R CCTCAGCCAGCTTCATCAGC 20 
600 
β-actin gene F GCCATGTACGTAGCCATCCA 20 
β-actin gene R ACGCTCGGTCAGGATCTTCA 20 
200 
αGSU gene F GCTGTCATTCTGGTCATGCT 20 
αGSU gene R GTAAATGCTTTGGCCACACA 20 
260 
Calcineurin A-F ATGTCCGAGCCCAAGGCGA 20 
Calcineurin A-R TCACTGGATATTGCTGCTAT 20 
1500 
NFAT1-F TACTCACCCACCAACCAGCA 20 
NFAT1a-R CCAGCTTTCTGAAGTGGCTG 20 
NFAT1b-R AAGGTGTGTGTCTATCAACT 20 
NFAT1c-R CTTCCTGATGATTTCATTAA 20 
260 
NFAT2-F ACATCATATATGAGCCCATC 20 
NFAT2-R GGTGGAGACAGTCTTCCCCG 20 
301 
NFAT3-F TCTACCAGGTGCACCGGATT 20 
NFAT3-R CATCGAGTGCTCCCAGCGCT 20 
282 
NFAT4-F TAATATGTCAGCGAGTATTG 20 
NFAT4-R GATCCAGTCACAATCATTTC 20 
261 
MEF2A-F ATGGGGCGAAAGAAGATACA 20 
MEF2A-R TTAGGTCACCCATGTGTCCA 20 
1500 
MEF2D-F ATGGGGAGGAAAAAGATTCA 20 
MEF2D-R TCACTTTAATGTCCAAGTAT 20 
1500 
Nur77-F GAAATTGTTCCCACCACCAG  20 
Nur77-R GTCTGTCCGTACAACTTCCT 20 
380 
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2.4.4 Real time PCR quantification analysis 
Real-time PCR was carried out using the SYBR green I dye with the ABI Prism 7700 
sequence detector (Perkin-Elmer Applied Biosystems). All PCR products were analyzed 
on agarose gels to ensure specificity of the amplification.  Primers used for real time PCR 
are shown in Table 2.18. 
 





Ubc4 F AATGACCTGGCTCGAGATC 20 
Ubc4 R GCAACCTTAGGCGGTTTGA 20 
 
150 
β-actin F GCCATGTACGTAGCCATCCA 20 
β-actin R ACGCTCGGTCAGGATCTTCA 20 
 
200 
           Table 2.18: Primers used for real time PCR analysis. 
 
The real time PCR reaction mix was assembled as shown in Table 2.19, and the cycling 
parameters are shown in Table 2.20. The templates were serially diluted fivefold in order 
to ensure that the dynamic ranges of both the target and reference were similar, and the 
comparative cycle threshold (CT) method was used to compare mRNA levels in the 
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Components Volume 
(µL) 
2×SYBR green mix (Applied Biosystems) 10 
Forward primer (4 µM) 1 
Reverse primer (4 µM) 1 
First strand cDNA 2 
Sterile distilled water 6 






Temperature (oC) Time 
1 1 50 2 min 
2 1 95 10 min 








Table 2.19:  Components of real time PCR reaction mix.  
   Table 2.20: Cycling parameters for real time PCR. 
  52  
2.5 Chloramphenicol acetyl transferase (CAT) assay 
After transfection for 48 h, cells from each well of a 6-well plate were rinsed once with 2 
mL HBSS (Hank’s Balanced Salt Solution, Sigma) and collected in 1 mL HBSS using a 
rubber policeman. The cells were collected and spun down at 960 × g for 5 min at 4 oC. 
The cell pellet was resuspended in 135 µL Harvest Buffer [0.5 % Triton X-100, 250 mM 
Tris-HCl (pH 8.0)] after discarding the supernatant and stored at -20 oC overnight to lyse 
the cells. After thawing, the cell debris was spun down at 20800 × g, 4 oC for 15 min. β-
galactosidase (β-gal) activity was assayed as described before (Sambrook et al., 1989). 
CAT assay was performed as follows: 110 µL of cell extract was heated at 65 oC for 10 
min, vortexed and centrifuged at 20800 × g for 5 min at 4 oC. The supernatant (100 µL) 




250 µCi/mL 3H-Acetyl CoA (Amersham Pharmacia Biotech) 0.8 
75 µM HCl 18.7 
200 mM chloramphenicol 0.5 
250 mM Tris (pH 7.8) 19.5 
5 mM Acetyl CoA 0.5 
Total volume 40 
        Table 2.21: Components of CAT reaction mix. 
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Subsequently, the mixture was incubated at 37 oC for 5 h, before the reaction was 
quenched with 800 µL of 5 M urea. The reaction mix was transferred to scintillation vials 
with 5 mL Econofluor-2 (Amersham). The contents were mixed well and radioactivity 
was counted for 5 min in WinspectralTM 1414 liquid scintillation counter.  
 
2.6 Luciferase assay 
Luciferase assay was carried out using the Promega Dual-Luciferase Reporter® Assay kit 
(Promega) and the Turner BioSystems Veritas™ Microplate Luminometer, and 
accompanying software. The experimental and control reporter genes are firefly and 
Renilla luciferase. The luciferase assay substrate reagent was prepared according to the 
kit instructions, and aliquots were stored at -70 °C. The Stop & Glo Reagent was 
prepared freshly each time just before use.  
 
The growth medium was removed and 20 µL PBS and 20 µL luciferase assay substrate 
reagent were added to each well.  After incubation for 10 min on a rotating platform at 
RT, the plate was inserted into the Luminometer for reading the firefly level. After three 
rounds of readings, the plate was removed, 20 µL Stop & Glo Reagent was added and 
after incubation for 10 min on a rotating platform at RT, the Renilla level was measured. 
 
2.6.1 Mammalian two-hybrid assay 
Cells were grown in 96-well white luminescent microplates (NUNC) until 50-70 % 
confluent. The cells were then transfected with the appropriate pGLuc-Gal4 (60 ng), pM 
(150 ng), pVP16 (150 ng) and pRL-CMV (2 ng) constructs, keeping the amount of DNA 
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transfected constant with pWhitescript (pWS) DNA. After 48 h, the luciferase levels were 
measured, as above. 
 
2.6.2. Promoter activity study 
The cells were transfected with the appropriate expression vectors (50-200 ng) along with 
the gene reporter constructs [human αGSU promoter (200 ng), rat LHβ promoter (200 ng) 
and pRL-CMV (5 ng) or pRL-SV40 (5 ng)], keeping the amount of DNA transfected 
constant with pWS DNA. After 48 h, the luciferase levels were measured, as above. 
 
2.7 Statistical analysis 
Statistical analysis to those above reporter gene assays was carried out using one way 
analysis of variance (ANOVA) followed by the Bonferroni t-test to determine means that 
were statistically different. Differences were considered significant when P<0.05. 
Assuming the data is normally distributed, standard error of the mean (SEM) was used to 
show how precisely of the mean for the population. All experiments were repeated at 
least three times and representative individual experiments or compiled results are 
presented. 
 
2.8 Western blot 
The cells were collected and spun down at 960 × g for 5 min at 4 oC. The cell pellet was 
resuspended in extraction buffer (Table 2.22) and lysed at 95 oC for 15 min. Cell debris 
was spun down and the supernatant was collected and protein content was measured 
using the Bradford method (Bradford, 1976; Biorad Bradford Protein Assay Reagent). 
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For separating cytoplasmic and nuclear proteins, the NE-PER Nuclear and Cytoplasmic 
Extraction Reagents Kit (Pierce) was used according to the manufacturer’s instructions. 
 
For each sample, 2xSDS loading dye (Table 2.22) was added to 25 µg of protein, and the 
mix was heated to 95 oC for 5 min before loading on a 10-12 % SDS-polyacrylamide gel 
in SDS running buffer (Table 22) at 100 V for 2 h at RT. The proteins were then 
transferred to an Immuno-Blot PVDF (Bio-Rad) membrane in transfer buffer (Table 2.22) 
at 30 V for 4 h at 4 oC. The membrane was then blocked with blocking buffer (Table 2.22) 
for 1 h at RT on a rotating platform. Subsequently, washing was carried out three times, 
10 min each with wash buffer (Table 2.22), on a rotating platform at RT before 
incubation with the primary antibody (Table 2.23) for 1 h at RT, or overnight at 4 oC, in 
dilution buffer (Table 2.22). Subsequently, washing was carried out as described above. 
The membrane was then incubated with the appropriate horseradish peroxidase (HRP) -
conjugated secondary antibody for 1 h at RT, or overnight at 4 oC, in dilution buffer. The 
membrane was then washed as described above and the immunoreactive protein was 
detected using the SuperSignal® WestPico Chemiluminescent substrate (Pierce) for 5 
min on a rotating platform. The membrane was rinsed with distilled water for 15 sec and 
autoradiography was performed using X-ray film (Kodak Scientific Imaging Film X-
OMATTM) in an autoradiograph cassette. Exposure was carried out for 0.5-3 min before 
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Table 2.22: Buffers used in western blot. 
 
Antibody Cat No. Source Dilution used 
ERα Sc-542 Santa Cruz Biotechnology 1:1000 
Ubc4 Sc-14998 Santa Cruz Biotechnology 1:1000 
Calcineurin A (CnA) AB1696 Chemicon International Inc. 1:500 
p-CaMKI Sc-28438 Santa Cruz Biotechnology 1:1000 
p-CaMKIV Sc-28443 Santa Cruz Biotechnology 1:1000 
GAPDH Sc-20357 Santa Cruz Biotechnology 1:1000 
PolII Sc-899 Santa Cruz Biotechnology 1:1000 
NFAT2 Sc-13033 Santa Cruz Biotechnology 1:1000 
NFAT3 Sc-13036 Santa Cruz Biotechnology 1:1000 
NFAT4 Sc-8321 Santa Cruz Biotechnology 1:1000 
Goat anti rabbit IgG-HRP Sc-2004 Santa Cruz Biotechnology 1:1000 
Bovine anti goat IgG-HRP Sc-2350 Santa Cruz Biotechnology 1:1000 





Extraction 4 % SDS in 1x PBS buffer. 
2x Loading dye 
100 mM Tris HCl pH 6.8,  200 mM BME, 4  % SDS, 0.2  % bromophenol 
blue, 20 % glycerol 
Running buffer 12.5 mM  Tris-HCl pH 7.4, 96 mM glycine, 1.7 mM SDS 
Wash buffer 20 mM Tris-HCl pH 7.4, 137 mM NaCl, with 0.1 % Tween-20 (add fresh)
Transfer buffer 40 mM glycine, 58 mM Tris, pH 8.3, 1.6 mM SDS and 20 % methanol 
Blocking buffer 1×TBST with 10 % non-fat milk 
Dilution buffer 1×TBST with 1 % non-fat milk 
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2.9 Subtractive hybridization 
The subtractive hybridization was carried out using the BD PCR-Select™ cDNA 
Subtraction Kit (BD Biosciences – Clontech). In brief, two different mRNA populations 
were converted into cDNA: the cDNA that contains specific (differentially expressed) 
transcripts as tester, and the reference cDNA as driver. Tester and driver cDNAs were 
hybridized, and the hybrid sequences were then removed. Consequently, the remaining 
unhybridized cDNAs representing genes that are expressed in the tester yet absent from 
the driver mRNA were amplified.  
 
2.9.1 RNA extraction and mRNA isolation 
Trizol (Invitrogen) was used to isolate the 100 µg total RNA from two groups of cells: 
αT3-1 and LβT2 cells; or untreated LβT2 and those treated with GnRH for 8 h. The 
mRNAs were isolated from of the total RNA using Oligotex® mRNA mini kit (Qiagen).  
 
2.9.2 cDNA synthesis and digestion 
Equal amounts of mRNA (2 µg) from the above two groups, and the control poly A+  
RNA (from human skeletal muscle) were reverse transcribed to ds cDNA and digested 
with RsaI according to the kit instructions. 
 
2.9.3 Ligation of tester with two different adaptors 
For the control tester, 1µl of skeletal muscle cDNA, was mixed with 5 µL of the diluted 
ΦX174/ Hae III control DNA (150 ng/mL). For each tester, the ligation mixture was 
combined in the order shown in Table 2.24. In another fresh microcentrifuge tube, 2 µL 
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of Tester 1-1 and 2 µL of Tester 1-2 were mixed as the unsubtracted tester control. The 
mix was incubated at 16 °C overnight. After ligation, the unsubtracted tester control was 
diluted in 1 mL of H2O. The samples were stored at –20 °C.  





Diluted tester cDNA 2  2  
Adaptor 1 (10 µM) 2   
Adaptor 2R (10 µM)   2  
Master mix 6  6  
Final volume 10  10  
       Table 2.24: The ligation reaction mix in subtractive hybridization.  
 
2.9.4 First hybridization 
For each group, the hybridization mix was combined in the order shown in Table 2.25. 
The samples were incubated at 98 °C for 1.5 min before incubation at 68 °C for 8 h. 





Diluted tester cDNA 1.5  1.5  
Adaptor 1-ligated tester 1-1 1.5  
Adaptor 2R-ligated tester 1-2  1.5  
 4X Hybridization buffer mix 1  1  
Final volume 4 4  
        Table 2.25: The first hybridization mix in subtractive hybridization.  
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2.9.5 Second hybridization 
For each group, the following reagents were added into a sterile tube: driver cDNA (1 
µL), 4X hybridization Buffer (1 µL), and sterile H2O (2 µL). The mixture was incubated 
at 98 °C for 1.5 min in a thermal cycler. The two first hybridization samples were mixed 
together in the presence of freshly denatured driver, and incubated at 68 °C overnight. 
Dilution buffer (200 µL) was added to the reaction, which was heat inactivated at 68 °C 
for 7 min in a thermal cycle, and the subtracted samples were stored at –20 °C. 
 
2.9.6 Primary PCR amplification   
The PCR mix was prepared for each group and control in the order as shown in Table 
2.26; 1 µL of each diluted cDNAs (including both subtracted sample and the 
corresponding unsubtracted tester) were aliquoted into the PCR mix, and incubated at 75 
°C for 5 min, before immediate thermal cycling, as shown in Table 2.27. 
Reagent Per Reaction 
 (µL) 
Sterile H2O 19.5  
10X Taq polymerase buffer (RGS) 2.5  
dNTP mix (10 mM) 0.5  
PCR primer 1 (10 µM) 1.0  
Taq polymerase (RGS) 0.5  
Total volume 24 
           Table 2.26: Preparation of the primary PCR mixture in subtractive hybridization. 
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Segment Cycle 
Temperature (oC) Time 
1 1 75 5 min 






3 1 72 5 min 
4 1 16 ∞ 
                  Table 2.27: Cycling parameters for the primary PCR in subtractive hybridization. 
 
2.9.7 Secondary PCR amplification   
PCR mix for the secondary PCR reactions was prepared in the order shown in Table 2.28; 
1 µL of each diluted primary PCR product was aliquoted into the PCR mix, before 
immediate thermal cycling, as shown in Table 2.29. 
 
Reagent Per Reaction 
 (µL) 
Sterile H2O 18.5  
10X Taq polymerase buffer (RGS) 2.5  
dNTP mix (10 mM) 0.5  
Nested PCR primer 1(10 µM) 1.0  
Nested PCR primer 2R (10 µM) 1.0  
Taq polymerase (RGS) 0.5  
Total volume 24 
                Table 2.28: Preparation of the secondary PCR mixture in subtractive hybridization. 
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Segment Cycle 
Temperature (oC) Time 






2 1 16 ∞ 
                 Table 2.29: Cycling parameters for the secondary PCR in subtractive hybridization. 
 
2.9.8 Ligation and sequencing the clones 
The second PCR products were ligated with pGEM-Teasy vector (Promega), and 
transformed. X-gal and IPTG were added onto the LB plates with Ampicillin (Sigma) for 
blue/white colony selection. Colony PCR was used to select the white clones with 
insertion, and the plasmid was isolated by miniprep and sequenced.   
 
2.10. Chromatin immunoprecipitation (ChIP)  
The protocol for ChIP has been described before (Koh, 2004). In brief, αT3-1 cells were 
grown to approximately 80 % confluence in 100 mm plate and counted. The proteins 
were cross-linked to DNA with 1 % formaldehyde (270 µL of 37 % formaldehyde in 10 
mL of culture medium) and incubated at RT with rotation for 10 min. Cross-linking was 
arrested by addition of 0.125 M glycine (1.25 mL of 1 M glycine in 10 mL of culture 
medium) and incubation at RT with rotation for 5 min. The culture medium was then 
aspirated and the cells were washed twice with 3 mL of cold PBS. The cells were then 
scraped with 2 mL of PBS and 2.5 x 106 cells were transferred into 1.5 mL microfuge 
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tubes. Cells were pelleted at 6800 × g for 10 min at 4 oC and resuspended in 800 µL of 
SDS lysis buffer containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride 
(PMSF), 1 µg/mL leupeptin and 1 µg/mL pepstatinA). The supernatant was discarded 
and the cell pellet resuspended in 900 µL of SDS lysis buffer (1 % SDS, 10 mM EDTA 
and 50 mM Tris-HCl pH 8.1) with protease inhibitors, and incubated on ice for 10 min. 
The samples were sonicated on ice with a MISONIX XL2020 sonifier to obtain DNA 
fragments of ~500 to 1000 bp, at setting 3 for 10 sec for 6 times, with a 10-sec rest 
between each pulse. The cells were then pelleted by centrifugation at 20800 × g at 4 oC 
for 10 min. 
 
The supernatant was transferred to a fresh 1.5 mL microfuge tube. To quantify the input 
DNA in the samples, 50 µL of the undiluted supernatant was removed as input and was 
stored at -20 oC until reverse crosslinking together with the precipitated samples. For the 
remainder of the supernatant, it was diluted with 2.25X volume of ChIP dilution buffer 
(0.01 % SDS, 1.1 % TritonX-100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1 and 167 
mM NaCl) with protease inhibitors. For pre-clearance of these pull-down samples, 40 µL 
of 50 % v/v Protein A-Sepharose CL4B beads (PAS, Amersham, UK) was added and the 
samples were incubated for 2 h with rotation at 4 oC. The sepharose beads were collected 
by centrifuging briefly at 100 × g for 1 min at 4 oC. The supernatant was transferred to 
fresh 1.5 mL microfuge tubes. Appropriate amounts of antibodies were added [MEF2 (15 
µL; Santa Cruz; sc-313×), Nur77 (15 µL; Santa Cruz; sc-5569)] and subsequently 
incubated overnight at 4 oC with rotation. 
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To collect the antibody-protein/DNA complex, 40 µL of PAS was added and incubated 
for 1 h at 4 oC with rotation. The sepharose beads were pelleted by gentle centrifugation 
at 100 × g for 1 min at 4 oC. The supernatant was discarded, and the PAS/antibody-
protein/DNA complexes were washed for 4 mins on a rotating platform with 1 mL of 
each of the buffers: (1) once with low salt wash buffer (0.1 % SDS, 1 % TritonX-100, 2 
mM EDTA, 20 mM Tris-HCl pH 8.1 and 150 mM NaCl); (2) once with high salt wash 
buffer (0.1 % SDS, 1 % TritonX-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1 and 500 
mM NaCl); (3) once with LiCl wash buffer (0.25 M LiCl, 1 % NP40, 1 % deoxycholate, 
1 mM EDTA and 10 mM Tris-HCl pH 8.1); (4) twice with 1x TE. After each wash, 
sepharose beads were collected at 100 × g for 2 min at 4 oC and the supernatant discarded. 
 
The associated DNA/protein/antibody complexes were eluted from the sepharose beads 
with 250 µL of freshly made elution buffer (1 % SDS and 0.1 M NaHCO3) with vigorous 
shaking at RT for 15 min. The eluant was collected and the elution was repeated. The 500 
µL eluted samples were reverse cross-linked with 20 µL of 5 M NaCl and 1 µL RNase 
(100 ng/µL), and were incubated at 65 oC for 4 h. Following this, 10 µL of 0.5 M EDTA, 
20 µL of 1 M Tris-HCl pH 6.5 and 2 µL of proteinase K (10 mg/mL) were added to the 
combined eluant and incubated for 1 h at 45oC. The precipitated DNA was then extracted 
by phenol/chloroform and precipitated with isopropanol/sodium acetate. Reverse 
crosslinking and precipitation were also carried out for the input DNA. The DNA was 
resuspended in 50 µL of sterile distilled water, to be used later on for PCR. The primers 
used in ChIP PCR are shown in Table 2.30. 
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mLH promoter (2701)F CAATCTGGGG GTTCAGCGAG 20 
mLH promoter (2941)R CCTTGGGCACCTGGCTTTAT 20 
 
241 
mFSH promoter-F GCCATGTACGTAGCCATCCA 20 
mFSH promoter-R ACGCTCGGTCAGGATCTTCA 20 
 
510 
Table 2.30: Primers used for amplification of the mouse LHβ and FSHβ promoters in ChIP. 
 
2.11 Plasmid immunoprecipitation (PIP) 
PIP was carried out as described before (Koh, 2004). The αT3-1 cells were grown to 
approximately 60 % confluency on 60 mm plates before transfection with 1 µg of the 
DNA constructs. Experiments were carried out as described in section 2.9 except that 
after cell lysis, the samples were not sonicated. Supernatants were transferred to fresh 
tubes and 50 µL were kept as input sample for DNA quantitation. The remainder was 
diluted with ChIP dilution buffer. Appropriate amounts of antibodies were added 
[NFATc4 (NFAT3, 15µL; Santa Cruz; sc-13036) and NFATc3 (NFAT4, 15 µL; Santa 
Cruz; sc-8321)], and immunoprecipitation was then carried out as described in section 
2.10. 
 
PCR quantification was carried out for the precipitated and input DNA using primers to 
the pGL2 basic vector controls as well as to the human αGSU proximal promoter as 
shown in Table 2.31. The PCR reaction and gel electrophoresis were carried out as 
described in section 2.4. 
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size (bp)  
pGL2 F AAGTTGGGTAACGCCAGGGT 20 
pGL2 R ACAAGGGTGAACACTATCCC 20 
404 
Human αGSU F TGTGTACAGCAGGGATCTAA 20 
Human αGSU R TTCAGGGTTGGATGCTCTGC 20 
295 
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CHAPTER 3   RESULTS 
 
3.1 Subtractive hybridization 
 
3.1.1 Subtractive hybridization of LβT2 and αT3-1 cells  
The αT3-1 and LβT2 cells represent different stages of embryonic gonadotrope 
development, and the β subunit genes are only expressed in the LβT2 cells. In order to 
elucidate additional mechanisms of basal transcription of the β genes, subtractive 
hybridization was carried out to determine the differentially expressed transcripts. The 
cDNA from αT3-1 cells was the driver, and cDNA from LβT2 cells was the tester. The 
efficiency of subtractive hybridization was confirmed using RT-PCR of GAPDH as 
control (not shown). From the subtracted library, 52 clones were selected and sequenced; 
due to some clones containing the same cDNA sequences, 25 genes were identified. The 
encoded proteins are likely involved in RNA splicing, protein modification and 
microtubule organization, while some of the sequences correspond to mitochondrial and 
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Function Accession No. Description 
Protein folding BC009007 Mus musculus chaperonin subunit 8 (theta), mRNA 
Transcription regulation BC034261        Mus musculus F-box and WD-40 domain protein 11, 
mRNA 




BC098459 Mus musculus cadherin 3, calcium-binding glycoproteins, 
mRNA 
Histone modification BC045160 Mus musculus DNA methyltransferase 1-associated 
protein 1, mRNA 
BC023039 Mus musculus anaphase-promoting complex (APC) 
subunit 11, mRNA  
Protein modification  
BC054834       Mus musculus protein kinase, cAMP dependent, catalytic, 
alpha, mRNA 
Protein degradation XM_131064 Mus musculus proteasome (prosome, macropain) subunit, 
beta type 4   (Psmb4), mRNA. 
Vesicle formation  BC056648 Mus musculus RAB14, member RAS oncogene family, 
GTP-binding protein 
BC038363          RNA binding motif protein 16, mRNA  
RNA splicing 
BC025849  RNA binding motif protein 15B, mRNA 
Apoptosis BC038825 Caspase 3, mRNA 
Signal transduction NM_078478       Growth hormone inducible transmembrane protein 
(Ghitm), mRNA 
BC085244 Pericentrin, centrosome protein involved in 
microtubule organization, mRNA 
NM_011655 Tubulin, beta 5, mRNA 
Cell growth/maintenance 
NM_026759 Mitochondrial ribosomal protein L13, mRNA 
BC021507 Oxysterol binding protein-like 9, mRNA 
BC012020 Mus musculus cDNA clone IMAGE:4500967 
NM_011045       Proliferating cell nuclear antigen (Pcna), mRNA 
BC076591 Nucleosome assembly protein 1-like 1, mRNA 
BC005668 RIKEN cDNA 1190017O12 gene 
BC026790 RIKEN cDNA 2510025F08 gene 
AC133523 Chromosome 19 clone RP23-34E20 









XM_127595 Similar to hypothetical protein XP_127595 
 
Table 3.1: The genes expressed in LβT2 but not αT3-1 cells, organized by primary function of gene 
product.  
Subtractive hybridization was carried out using the cDNA from αT3-1 cells as driver and the cDNA from 
LβT2 cells as tester. 
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3.1.2 Subtractive hybridization of LβT2 cells with and without GnRH treatment 
The mouse gonadotrope LβT2 cell line expresses the LHβ gene, and both LHβ and FSHβ 
genes are up-regulated by GnRH treatment (Graham et al., 1999; Turgeon et al., 1996). 
To determine the global profile of transcripts that are specifically regulated by GnRH in 
LβT2 cells, subtractive hybridization was carried out on untreated LβT2 cells and those 
treated with GnRH for 8 h. Although early cellular responses to GnRH in the 
gonadotropes, such as kinase phosphorylation, and activation of the early response 
factors happen rapidly, often within 1 h, previous RT-PCR and promoter studies in our 
lab have shown that the maximal activation of LH and FSH occurs after GnRH treatment 
for 8 h (unpublished). The cDNA from untreated LβT2 cells was selected as driver and 
that from GnRH treated cells was selected as tester. For the control, human skeletal 
muscle cDNA was the driver, and a mix of skeletal muscle cDNA with ΦX174/ Hae III 
control DNA was the tester. The PCR products for the control and the experimental 
samples after the subtractive hybridization are shown in Fig 3.1 and Fig 3.2, respectively. 
The efficiency of subtractive hybridization was confirmed by using RT-PCR of GAPDH 
as control (Fig 3.3). The secondary PCR products from subtracted samples were ligated 
with pGEM-Teasy vector (Promega), and about 48 clones were selected and sequenced, 
of which cDNA encoding 20 individual proteins was identified. These proteins include 
those that are likely involved in signal transduction, cell proliferation and metabolism, or 
with unknown functions (Table 3.2). Most of the identified proteins have not previously 
been shown to be regulated by GnRH.  
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The differential expression following GnRH treatment of two of the genes, calcineurin 
catalytic subunit and ubiquitin-conjugating enzyme 4 (ubc4), was confirmed by RT-PCR, 
and their possible functions in mediating GnRH response were investigated further as 
reported in sections 3.2, 3.3 and 3.4. 
 
 







Fig 3.1: The subtracted PCR products for the control skeletal muscle cDNA.  
Lane 1 contains the primary PCR products of subtracted control sample, lane 2 contains the primary PCR 
products of unsubtracted control sample, lane 3 contains the 1 kb marker, lane 4 contains the secondary 
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Fig 3.2: The subtracted PCR products for the LβT2 cDNA following GnRH treatment.  
Lane 1 contains the primary PCR products of unsubtracted samples, lane 2 contains the primary PCR 
products of subtracted samples, lane 3 contains the secondary PCR products of unsubtracted samples, lane 










Fig 3.3: Subtractive efficiency was confirmed by reduction of GAPDH abundance after PCR-select 
subtraction. 
Tester cDNA was prepared with poly A+ RNA from LβT2 after GnRH treatment (100 nM, 8h). Driver 
cDNA was prepared with poly A+ RNA from untreated LβT2 cells. PCR was performed with the 
subtracted (Lanes1–3) or unsubtracted (Lanes 5–7) secondary PCR products, using GAPDH 5' and 3' 











Protein dephosphorylation J05479 Mus musculus Calmodulin-dependent calcineurin A subunit, 
alpha isoform, mRNA    
Protein ubiquitination BC003923 Mus musculus Ubiquitin-conjugating enzyme 4 (ubc4), 
mRNA 
Protein degradation NM_027357   Mus musculus proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 1 (Psmd1), mRNA 
Protein transport BC046792 Mus musculus ADP-ribosylation factor-like 6 interacting 
protein 1, mRNA 
BC082588 Mus musculus Transducer of erbB-2.1 , mRNA 
  
Signal transduction 
U67187 Mus musculus G protein signaling regulator RGS2 (rgs2) 
mRNA 
RNA splicing  BC043060 Mus musculus FUS interacting protein (serine-arginine rich) 
1, mRNA 
Cell communication NM_009846 Mus musculus CD24a antigen (Cd24a), mRNA 
 
P58501 Mus musculus GC-rich sequence DNA-binding factor 
homolog 
Transcription factor 
X14678 Mus musculus TPA-induced TIS11, mRNA 
 
Histone-binding BC004693 Mus musculus Nuclear autoantigenic sperm protein 
 




BC059089 Mus musculus exosome component 8, mRNA  
 
NM_007505   Mus musculus ATP synthase, H+ transporting, mitochondrial 
F1 complex, alpha subunit, isoform 1 (Atp5a1), mRNA 
 
Ion transport 
NM_009320   Mus musculus solute carrier family 6 (neurotransmitter 
transporter, taurine), member 6 (Slc6a6), mRNA 
AK145983 Mus musculus 14 days pregnant adult female placenta cDNA 
 
BC002231 Mus musculus nucleolar protein 5A, mRNA 
 
S15785 Mus musculus Heat-stable antigen-related hypothetical 
protein HSA-C 







BC031856 Mus musculus RIKEN cDNA 1110036O03 gene, mRNA  
 
Table 3.2: The genes up-regulated in GnRH-treated cells, organized by primary function of the gene 
product. 
Subtractive hybridization was carried out using the cDNA from LβT2 cells treated with GnRH for 8 h as 




  72  
3.2 GnRH induction of ubc4 expression promotes estrogen receptor ubiquitylation 
and trans-activation of the LHβ gene 
 
3.2.1 GnRH induces ubc4 expression in LβT2 cells 
One of the clones in the subtracted library whose expression was increased following 
GnRH treatment in LβT2 cells, contained the coding sequence of the ubiquitin-
conjugating enzyme 4 (ubc4). The effects of GnRH on the mRNA levels of this gene 
were confirmed by real time PCR, which showed a continuing increase in transcript 
levels between 1 to 8 h exposure to GnRH, reaching nearly 9-fold that in the control cells 
by 8 h, while levels of β-actin remained unchanged (Fig 3.4).  Western analysis of LβT2 
cell lysate confirmed that ubc4 protein levels are higher in LβT2 cells following GnRH 



































Fig 3.4: The mRNA levels of ubc4 increase following GnRH treatment in LβT2 cells. 
The real-time PCR was carried out in LβT2 cells following GnRH-treatment (100 nM, 0-8 h) and the 
















Fig 3.5: GnRH treatment increases the protein levels of ubc4. 
LβT2 cells were lysed from control cells, those treated with GnRH (100 nM, 8 h), and those in which ubc4 
was over-expressed. The cell extract was run on 15 % SDS gel before Western analysis using antisera to 
Ubc4 (upper panel) or GAPDH (lower panel) as control for protein loading. The apparent molecular weight 
of the target protein is shown in brackets. 
 
 
   (17 KDa) 
   (37 KDa) 
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3.2.2 Over-expression of ubc4 reduces ERα protein levels, as does GnRH 
Ubc4, as a component of the ubiquitin-proteasome pathway, is involved in the 
proteasome-dependent degradation of target proteins. At the same time, ligand-dependent 
ERα degradation through the ubiquitin-proteasome pathway has been reported, and is 
linked to the ERα transactivation activity. In order to examine whether GnRH-activated 
ubc4 is involved in regulating ERα degradation, the effects of ubc4 on ERα protein levels 
were investigated. A ubc4 expression vector and siRNA construct designed to knock 
down ubc4 expression were first constructed. Western blotting validated that ubc4 
expression levels were substantially reduced by the siRNA construct (Fig 3.6). Western 
analysis also showed that transfection of siubc4 increased ERα protein levels, while 
transfection of the siGFP pSUPER plasmid as a negative control did not alter ERα 
protein levels (normalized value 0.99 ± 0.03 fold of untreated controls; not shown), 
which indicates that ubc4 is involved in reducing ERα protein levels. Over-expression of 
ubc4 reduced the ERα protein levels (normalized value 0.54 ± 0.13 of untreated controls; 
representative gel shown in Fig 3.6) and GnRH treatment also reduced the ERα protein 
levels (Fig 3.6). Furthermore, transfection of siubc4 inhibited the GnRH reduction of 
ERα protein levels (Fig 3.6), which suggests that ubc4 mediates the GnRH inhibition 
effects on ERα protein levels.  
 
In order to confirm the GnRH effects on ERα protein levels, the LβT2 cells were exposed 
to a time course GnRH treatment for 1-24 h, after which western analysis was carried out 
to detect changes in ERα protein levels. The ERα protein level was slightly reduced after 
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2 h GnRH exposure, barely detectable after 8 h and undetectable after 24 h; a similar 

















Fig 3.6: Transfection of siRNA to knockdown ubc4 increases ERα protein levels in cells exposed to 
GnRH. 
Protein levels of ubc4 (top panel), ERα (middle panel) and GAPDH (lower panel) were measured in LβT2 
cells following ubc4 over-expression or transfection of a construct to block its expression (siubc4), with or 
without GnRH (100 nM, 8 h) treatment. The anti-ubc4 gel is from a separate gel, but using the same 
samples with the same amount as anti-ERα and anti-GAPDH gel, which validated the successful knock-
down of ubc4. The first lanes for anti-ERα and anti-GAPDH are taken from different parts on the same gel. 
In LβT2 cells, the apparent molecular weight of the ERα isoform is 50-55KDa. The apparent molecular 












Fig 3.7: GnRH exposure of gonadotropes causes a reduction in ERα protein levels. 
LβT2 cells were cultured and exposed to GnRH (100 nM, 0-24 h). The cells were lysed and the cell extract 
was run on 12 % SDS gel before western analysis using antisera to ERα (upper panel) or GAPDH (lower 




      (17 KDa) 
(50-55 KDa) 
  (37 KDa) 
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3.2.3 GnRH reduction of ERα protein levels in gonadotropes is proteasome 
dependent 
Previous studies in MCF-7 cells showed that E2-induced ERα degradation involves the 
proteasome pathway. The role of the proteasome pathway in the inhibitory effect of 
GnRH on ERα protein levels in gonadotrope cells was therefore investigated. LβT2 cells 
were exposed to GnRH or E2 for 24 h, in the presence or absence of the proteasome 
inhibitor MG132. The GnRH and E2 treatments both reduced the level of the ERα, but in 
both cases addition of MG132 blocked this effect, which suggests that GnRH-induced 















Fig 3.8: Proteasome inhibitor MG132 abates the GnRH effect on ERα protein levels. 
LβT2 cells were cultured and some were exposed for 24 h to 10 nM E2 or GnRH (100 nM, 8 h), in the 
absence or presence of MG132, and protein levels of ERα (upper panel) and GAPDH (lower panel) were 
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3.2.4 The liganded ERα transactivates LHβ directly in synergy with Sf-1 and Pitx1 
without requiring a consensus ERE 
In order to understand how GnRH-mediated degradation of ERα affects its 
transactivation, we sought first to elucidate the mechanism of ERα activation of the LHβ 
gene promoter. Promoters from the LHβ genes of rat (rLHβ, the proximal 1.2 kb) and 
Chinook salmon (csLHβ; the proximal 3.3 kb), ligated to CAT reporter genes, were 
transfected into COS 1 cells to test their responsiveness to ERα and E2. Only the csLHβ 
gene promoter responded to ERα+E2 alone, but the activity of both promoters increased 
dramatically when ERα was transfected together with Sf-1 and Pitx1 expression vectors, 
reaching levels 40 to 60-fold those in unstimulated cells. This effect was dependent on 
the presence of E2. However, the near-consensus ERE on the csLHβ proximal promoter 
was subsequently removed, and the synergistic effect was still apparent (Fig 3.9a-c, 
carried out together with Koh Mingshi). The levels of reporter gene activity in cells 
transfected with the promoterless CAT vector were unaltered by ERα over-expression 
(not shown). Further experiments were carried out to clarify the relative importance of 
Sf-1 and Pitx1 for the synergy with ERα+E2 on the rLHβ promoter, using the rLHβ-luc 
construct. Although ERα over-expression alone failed to increase basal rLHβ promoter 
activity, it increased the effects of Sf-1 or Pitx1 by six- or two-fold, respectively, while 
increasing the combined effects of Sf-1 and Pitx1 by as much as seven-fold (Fig 3.9d). 
Similar experiments on the csLHβ promoter construct have been carried out previously, 
revealing the synergistic action of ERα with Sf-1 alone which is increased further with 
the addition of Pitx1, while ERα does not act synergistically with Pitx1 alone (Le Dréan 
et al., 1996; Melamed et al., 2002). 





















Fig 3.9: The liganded ERα transactivates two vertebrate LHβ  gene promoters in synergy with Sf-1 
and Pitx1. 
(A) The rLHβ promoter-CAT6, (B) the csLHβ 289 bp proximal promoter-CAT3, (C) the longer 3.3 kb 
csLHβ promoter-CAT3 with or without deletion of the ERE (at -260 bp), or (D) the rLHβ promoter 
luciferase constructs were transfected into COS-1 cells alone, with ERα, Sf-1 and/or Pitx1 expression 
vectors. For (A) and (B), as indicated, cells were exposed to 10 nM E2 at the time of transfection; for (C) 
and (D) all cells transfected with ERα were exposed to E2. Cells were harvested and reporter-gene levels 
assayed and normalized values are expressed as fold over those in control cells. (A-C) Statistical analysis 
(ANOVA followed by Bonferroni t-test) compared mean values separately for groups with and without E2 
(for Figs A-B), or for intact- and ERE-deleted promoter constructs (for Fig C), and similar values (P>0.05) 
are designated the same letter in upper (for control and intact constructs) or lower case (for E2 treated or 
ERE-deletion construct). (D) Welch’s t-test was used to compare means of treatments with and without 
cotransfection of ERα +E2; * (P<0.05), ** (P<0.005). Mean ± SEM, n=4-6. 
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The above results showed that ERα activates the csLHβ promoter without requiring the 
near-consensus ERE on the proximal promoter, and ERα also activates the rLHβ 
promoter despite its lack of a consensus ERE, although a distal putative ERE has 
previously been reported for rat (Shupnik and Rosenzweig, 1991). Thus any direct 
actions of the liganded ER on the LHβ gene promoter, if they occur, are likely to involve 
other DNA binding factors, as shown for example for Sp1 and AP-1 (Hall et al., 2001). In 
order to elucidate the DNA binding factors responsible for ERα transactivation, site-
directed mutagenesis was carried out to delete the REs for the various transcription 
factors, and the effect of ERα over-expression was tested. The csLHβ gene promoter 
shows a clear response to ERα over expression, which was reduced with removal of the 
ERE or Sf-1 REs, while deletion of the Pitx1-RE had no effect (Fig 3.10a). Notably, the 
effect of ERE deletion to reduce slightly the basal promoter activity differed from that 
seen in the COS 1 cells, where the deletion gave rise to higher levels of promoter activity 
(e.g. Fig 3.9c). In contrast to the csLHβ gene promoter activity, the rLHβ gene promoter 
is not responsive to ERα-expression alone, but only when Sf-1 and Pitx1 are also over 
expressed; this additive effect of ERα on the stimulation by Sf-1+Pitx1 requires both the 
Sf-1 and Pitx1 REs (Fig 3.10b). 
 































Fig 3.10: The response elements required for the activation of the LHβ gene promoters by ERα. 
(A) The intact csLHβ-CAT construct, or the same construct lacking the ERE, Sf-1RE or Pitx1RE or 
combinations of their deletions, were transfected into LβT2 cells; (B) alternatively, the intact rLHβ-CAT 
construct or the same construct lacking the distal ERE, both Sf-1REs or the Pitx1RE were transfected into 
COS 1 cells, all with or without co-transfection of the ERα expression vector and exposure to E2. After 48 h, 
cells were harvested and CAT/β gal levels assayed and presented as in Fig 3.9. Statistical analysis 
(ANOVA followed by Bonferroni t-test) compared mean values separately for groups with or without ERα, 
and similar values (P>0.05) are designated the same letter in upper or lower case. Additional analysis 
compared means for the same promoter constructs with or without ERα and only those significantly 
different are shown (*: p<0.05). Mean ± SEM, n=3-4. 
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3.2.5 GnRH-induced ubc4 enhances ERα transactivation of the LHβ gene 
Having shown that ubc4 regulates ERα protein levels and ERα stimulates LHβ gene 
transcription, the effect of ubc4 on the ERα stimulation of LHβ was then investigated. 
LβT2 cells were transfected with the csLHβ-CAT construct and exposed to GnRH, and 
some were co-transfected with ERα and exposed to E2. Some of these cells also had the 
siubc4 construct co-transfected. Validation of the successful knock-down of ubc4 has 
been shown by Western analysis (Fig 3.6).  GnRH or ERα (with E2) alone increased 
promoter activity by around 7- or 12-fold over controls, while a combination of both 
treatments increased activity to nearly 35-fold that in control cells. Co-transfection of the 
siubc4 led to a drop in promoter activity in all cells treated with GnRH, or less so, in cells 
in which the ERα was over expressed alone (Fig 3.11a); transfection of the siGFP 
pSUPER plasmid as a negative control did not alter transactivation of the LHβ gene by 
ERα, with or without GnRH (not shown). Conversely, the effect of ERα over-expression 
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Fig 3.11: Ubc4 is involved in mediating the effect of GnRH on the LHβ gene and increases ERα 
transactivation. 
LβT2 cells were transfected with the csLHβ promoter-CAT construct with or without ERα expression 
vectors, and/or exposed to GnRH, as marked. All cells co-transfected with ERα were also exposed to E2.  
Some of the cells were also transfected with the (A) siubc4 construct or (B) ubc4 expression vector. After 
48 h, cells were harvested and CAT/β gal levels assayed. Statistical analysis (ANOVA followed by t-test) 
compared pairs of means for each treatment group, with and without co-transfection of siubc4 or ubc4 
expression vector; statistically different means are designated ** (P<0.01) or *** (P<0.001); others are not 
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3.2.6 Ubc4 increases the synergistic effect of ERα with Sf-1 and Pitx1 on the LHβ 
promoter 
In order to test whether ubc4 increases the already synergistic effect of ERα with Sf-1 
and Pitx1 on the csLHβ promoter, ERα was over expressed with or without ubc4, or 
together with Sf-1 and Pitx1 expression vectors in COS 1 cells and the effects on csLHβ 
promoter activity were measured. The addition of ubc4 increased the synergistic effect of 






















Fig 3.12: Ubc4 increases ERα transactivation, and the synergistic effect of ERα with Sf-1 and Pitx1. 
COS 1 cells were transfected with the csLHβ promoter-CAT construct with or without ERα, Pitx1 and Sf-1 
expression vectors, as marked. All cells co-transfected with ERα were also exposed to E2. Some of the cells 
were also transfected with the ubc4 expression vector. After 48 h, cells were harvested and CAT/β gal 
levels assayed and presented as in Fig 3.10. Statistical analysis (ANOVA followed by t-test) compared 
pairs of means for each treatment group, with and without co-transfection of ubc4 expression vector; 
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3.2.7 Ubc4 over-expression increases the interaction of ERα with Sf-1 or Pitx1 
In order to elucidate the mechanisms through which ubc4 enhances ERα transactivation 
of the LHβ gene, the possibility that ubc4 alters ERα protein-protein interactions with 
other transcription factors was tested. Two-hybrid assays were performed in LβT2 cells 
using ERα fused to the Gal4 DBD together with ERα, Sf-1 or Pitx1 fused to the VP16 
AD, and a Gal4-responsive luciferase reporter gene. Some of the cells were also co-
transfected with the ubc4 expression vector. Background levels of reporter gene 
activation by the Sf-1, Pitx1 or ERα fused to the VP16 AD, or the ERα fused to the Gal4 
DBD, where present, were subtracted from the values of the interacting protein; any 
activity by these constructs alone was unaffected by ubc4 over-expression (not shown). 
Luciferase activity was elevated in cells transfected with ERα-Gal4DBD together with 
Sf-1-VP16AD, Pitx1-VP16AD or ERα-VP16AD, and the activity was further increased 
for all these pairs following ubc4 over expression (Fig 3.13). Similar studies were carried 
out to test the effect of GnRH exposure on these interactions, which increased generally 
to a lesser extent than seen following ubc4 over-expression, although the interaction of 
ERα with Pitx1 reached over three-fold that in the absence of GnRH (not shown). 
 
In this study, therefore, GnRH was seen to increase ERα degradation and transactivation 
of the LHβ gene, apparently through stimulation of ubc4 expression. It was further 
demonstrated that the stimulatory effect of ERα on LHβ expression is mediated through 
interactions with other regulatory transcription factors Sf-1 and Pitx1 on the proximal 
promoter, without necessarily requiring an ERE. Mammalian two-hybrid assays indicate 
that ERα dimerization and its interactions with Pitx1 and Sf-1 increase when ubc4 is 
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over-expressed. ERα activity is thus modified by GnRH-mediated ubiquitination, which 





















Fig 3.13: Ubc4 increases ERα interaction with Sf-1 and Pitx1. 
Two-hybrid assays were carried out in LβT2 cells using a Gal4 DBD-ERα fusion construct with VP16 AD 
fused to ERα, Pitx1 or Sf-1, the Gal4-responsive reporter gene and a Renilla luciferase construct for 
internal control; all cells were exposed to E2 (10 nM) at the time of transfection. Luciferase activity was 
measured 40 h after transfection and is calculated, after normalization and subtraction of any activity of the 
fusion constructs alone, as fold over the levels in the negative control in which unfused Gal4 DBD and 
VP16 AD constructs were transfected (basal level). Statistical analysis (ANOVA followed by t-test) 
compared pairs of means for each treatment group, with and without co-transfection of ubc4 expression 
vector; statistically different means are designated * (P<0.05), ** (P<0.01); others are not significant (N.S.). 
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3.3 Calcineurin is involved in the GnRH activation of the αGSU gene promoter  
 
3.3.1 Calcineurin catalytic subunit A expression levels increase in response to GnRH 
Amongst the genes induced by GnRH in gonadotrope cells identified by subtractive 
hybridization, was the calcineurin catalytic subunit A (CnA). In order to confirm the 
subtractive hybridization results, RT-PCR was carried out to compare the mRNA levels 
of CnA with and without GnRH treatment. The CnA transcript levels in αT3-1 cells 
increased after GnRH treatment for 8 h, while the internal control β-actin levels remained 
unchanged (Fig 3.14). To detect changes in the CnA protein levels, gonadotrope αT3-1 
cells were exposed to GnRH for 0-8 h, after which western analysis was carried out. The 
CnA protein levels increased after 2 h GnRH exposure, and this was still apparent after 8 





























Fig 3.14: GnRH exposure of gonadotropes is followed by an increase the mRNA levels of CnA. 
αT3-1 cells were treated with GnRH (100 nM, 8 h), after which RNA was extracted from treated and 
untreated control cells. The primers amplified the 1.5 kb full-length of CnA cDNA. Amplification of a 














Fig 3.15: GnRH exposure of gonadotropes is followed by an increase in CnA protein levels. 
αT3-1 cells were cultured and exposed to GnRH for 0-8 h. The cells were lysed and the cell extract was run 
on 10 % SDS gel before western analysis using antisera to CnA (upper panel) or GAPDH (lower panel) as 
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3.3.2 Calcineurin mediates the basal and GnRH stimulatory effect on the human 
αGSU gene promoter  
The human αGSU gene promoter exhibits robust GnRH-induced activity, which provides 
a good model to investigate the mechanism for GnRH regulation of gonadotropin gene 
expression. In this section, the mechanisms of calcineurin in mediating GnRH effects on 
the human αGSU promoter were investigated. Firstly, luciferase assays confirmed the 
stimulatory effect of GnRH on human αGSU promoter activity in the αT3-1 cells: GnRH 
increased human αGSU promoter activity more than 30-fold (Fig 3.16). In order to 
examine whether calcineurin is involved in mediating GnRH effects on this gene, the 
effect of its inhibitor cyclosporine A (CsA) was investigated, and it clearly reduced both 
basal activity and the GnRH effect on the human αGSU promoter activity. Furthermore, 
over-expression of CnA increased the basal αGSU promoter activity by nearly 3-fold, but 
no additive effects on the GnRH-induced αGSU promoter activity were apparent (Fig 
3.16).  
 
Considering that CsA might have non-specific effects, an siRNA construct targeting CnA 
was constructed (siCnA). Validation of successful knock down of CnA was shown by 
Western analysis (Fig 3.17). Luciferase assays showed that transfection of this siRNA 
construct to knockdown CnA expression also decreased basal activity and the GnRH 
effect on the human αGSU promoter activity (Fig 3.18). 
 
Given that PKC and calcium pathways are activated in the GnRH signaling pathway, 
luciferase assays were carried out to investigate the possible crosstalk between 
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calcineurin and these pathways in activation of human αGSU promoter. Activation of 
PKC and calcium through treatment with the phorbol ester (PMA) and ionomycin in αT3-
1 cells, doubled the human αGSU promoter activity (Fig 3.19). The constitutively active 
CnA (CA-CnA) expression vector with deletion of the CaM-binding site and adjacent 
auto-inhibitory domains on CnA was constructed. Luciferase assays showed that co-
transfection of CA-CnA with PMA/Io treatment synergistically increased the promoter 
activity, reaching nearly 16-fold that of control. This suggests that calcineurin-regulated 
and PMA/Io–triggered signaling pathways may converge to induce human αGSU gene 
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Fig 3.16: Effects of inhibition of calcineurin by CsA on the human αGSU gene promoter activity.  
Gonadotrope αT3-1 cells were transfected with 200 ng of human α-luc construct and 100 ng calcineurin 
catalytic subunit A expression vector (CnA EV). Transfected cells were pretreated with CsA (10 µM, 30 
min), after which they were exposed to GnRH (100 nM, 8 h). Luciferase assays were carried out and the 
levels of luciferase normalized to levels of Renilla, the results are expressed as fold induction over the 
human α-luc control-transfected cells without treatment. Statistical analysis (ANOVA followed by 
Bonferroni t-test) compared the mean values separately for groups with and without GnRH. Means 
designated by the same letter are not significantly different (P>0.05). Additional analysis compared means 
for each treatment group with and without GnRH; statistically different means are designated *** 
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Fig 3.17: Western analysis to confirm siRNA knockdown of CnA protein. 
αT3-1 cells in 6-well plate were transfected with 2 µg siRNA construct created to target the CnA (siCnA) 
for each well. The control was transfected with 2 µg empty pSUPER vector. After transfection for 60 h, the 
cells were harvested and proteins were extracted before analyzing with antisera to CnA (upper panel) or 







Fig 3.18: Effects of siRNA knockdown of calcineurin on the human αGSU gene promoter activity.  
αT3-1 cells were transfected with 200 ng of human α-luc construct and some also with 100 ng siRNA 
construct created to target the CnA (siCnA). Transfected cells were stimulated with GnRH at100 nM, for 8 
h. Luciferase assays were carried out after 60 h, and the levels of luciferase normalized to levels of Renilla; 
the results are expressed as fold induction over the human α-luc control-transfected cells without treatment. 
Statistical analysis (ANOVA followed by Bonferroni t-test) compared the mean values separately for 
groups with and without GnRH treatment. Means designated by the same letter are not significantly 
different (P>0.05). Additional analysis compared means for each treatment group with and without GnRH; 
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Fig 3.19: Effects of over-expression of CA-CnA on the human αGSU gene promoter activity.  
αT3-1 cells were transfected with 200 ng of human α-luc construct and some also with 100 ng of 
constitutively activate calcineurin expression vector (CA-CnA EV). Some of the transfected cells were 
stimulated with PMA (10 nM, 6 h) and ionomycin (100 nM, 6 h). Luciferase assays were carried out and 
the levels of luciferase normalized to levels of Renilla; the results are expressed as fold induction over the 
human α-luc control-transfected cells without treatment. Statistical analysis (ANOVA followed by 
Bonferroni t-test) compared the mean values separately for groups with and without PMA/Io treatment. 
Means designated by the same letter are not significantly different (P>0.05). Additional analysis compared 
means for each treatment group with and without PMA/Io treatment; statistically different means are 
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3.3.3 The calcineurin target, NFAT, is necessary for the human αGSU promoter 
activity  
Calcineurin is shown to be required for both basal and GnRH stimulation of the human 
αGSU promoter activity, however, the mechanisms involved in this process need to be 
elucidated. The typical mechanism for calcineurin to stimulate gene expression involves 
activating its downstream transcription factors; one of the most extensively investigated 
is the nuclear factor of activated T cells (NFAT). A possible role for NFAT in mediating 
calcineurin effects on the human αGSU gene was therefore investigated.  
 
Firstly, RT-PCR was carried out to check the presence of NFAT in the gonadotrope αT3-
1 cells (Fig 3.20). With the αT3-1 total cDNA as template, the primers for each NFAT 
isoform were used. The results indicate that three isoforms of NFAT: NFAT2, NFAT3, 
and NFAT4 are present in αT3-1 cells (Fig 3.20).  
 
Fig 3.20: RT-PCR analysis of the expression of NFAT in αT3-1 cells.  
Total RNA was extracted from αT3-1 cells, and 5 µg RNA was used for RT reaction, followed by PCR 
using specific primer sets for each mRNA. The figure shows photographs of the ethidium bromide-stained 
products using agarose gel electrophoresis. The primers amplified a 260 bp cDNA fragment of NFAT1a, b, 
and c, a 301 bp cDNA fragment of NFAT2, a 282 bp cDNA fragment of NFAT4, and a 261 bp cDNA 
fragment of NFAT3. Bands corresponding to NFAT2, NFAT4 and NFAT3 mRNAs were amplified. 









5. NFAT4 (NFATc3) 
6. NFAT3 (NFATc4) 
7. No template control
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Calcineurin-mediated NFAT activation usually involves dephosphorylation and 
translocation of NFAT to the nucleus (Chow et al., 1999). The ability of GnRH and CsA 
to alter relative levels of NFAT in the cytoplasm and nucleus was therefore investigated. 
Firstly, the cytoplasmic and nucleic proteins were isolated from GnRH, and/or CsA 
treated αT3-1 cells, then Western blot using antisera specific to each NFAT isoform was 
carried out. NFAT2 was only detected in the nucleus, and protein levels remained almost 
constant after GnRH, and/or CsA treatment. However, NFAT3, although also detected 
only in the nucleus, had increased protein levels in response to GnRH, and this increase 
was abolished when combined with CsA treatment. For NFAT4, CsA treatment lead to 
an increase in protein levels in the cytoplasm, and a decrease in the nucleus, however, an 
increase in this protein level in the nucleus was not seen following the GnRH treatment. 
The protein levels for cytoplasmic and nuclear loading controls GAPDH and PolII, 
remained unchanged (Fig 3.21). These results suggest that among the three NFAT 
isoforms, GnRH activates NFAT3 through calcineurin by up-regulation of its proteins 
levels in the nucleus, while NFAT4 protein level in the nucleus is not affected by GnRH, 





































Fig 3.21: The relative protein levels of NFAT3 in the nucleus increases following GnRH treatment.  
αT3-1 cells were treated by CsA (10 µM, 30 min) before exposure to GnRH (100 nM, 1 h). Controls 
comprised untreated cells. The cells were lysed, and cytoplasmic and nuclear extracts were run on 8 % SDS 
gel before western analysis using antisera to NFAT2, 3 or 4 (upper panels) or GAPDH and PolII (lower 
panel) as control for protein loading. C, cytoplasmic proteins; N, nucleic proteins. The apparent molecular 
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The possibility that NFAT is associated with the human αGSU promoter was then 
investigated by utilizing a novel plasmid immuno-precipitation (PIP) assay (Koh, 2004). 
The pGL2 basic vector containing the human αGSU promoter was transfected into αT3-1 
cells, before cross-linking and immuno-precipitation with specific NFAT antibody to pull 
down the NFAT associated DNA. Primers on the human αGSU promoter were then used 
to amplify the promoter region. In order to exclude the false positive results due to NFAT 
association to the pGL2 basic vector backbone, the promoterless pGL2 basic vector was 
also transfected into αT3-1 cells at the same time, and the primers on the vector were 
used. Because the NFAT2 protein level appears not to be affected by either GnRH or 
CsA, the PIP assays focused on NFAT3 and NFAT4. The results indicate that NFAT3 is 
associated with the human αGSU promoter following GnRH treatment, but not at basal 
conditions (Fig 3.22). However, NFAT4 is constitutively associated with the human 
αGSU promoter at both basal and GnRH-stimulated conditions (Fig 3.23). The negative 
control showed that neither NFAT3 nor NFAT4 is associated with the promoterless pGL2 
basic vector, which indicates the specificity for NFAT3 and NFAT4 association with the 













































Fig 3.22: NFAT3 is associated with the human αGSU promoter following GnRH treatment. 
Human-αGSU promoter 1.2 kb construct (1 µg) was transfected into 60 mm plate of αT3-1 cells. The cells 
were treated with GnRH (100 nM, 8 h) before harvest and fixed with formaldehyde and lysed. PIP was 
carried out using antibody to NFAT3. PCR analysis using specific primers on the promoter (A) and the 
vector backbone (B) were carried out on the precipitated DNA (upper panel) and the input (lower panel). 
All pull downs were carried out in duplicates, with and without the antibody.  
 
 
- + - - + + - - + +
- - - - - - + + + +
- - + + + + + + + +
- - - + +
- + + + +
+ GnRH
+ NFAT3 Ab 
+ GnRH  
+ human-αGSU promoter
Precipitated  
+ pGL2 basic vector
+NFAT3 Ab
+ + + +






+ pGL2 basic vector
+NFAT3 Ab
+ + + +
- - + +
+ human-αGSU promoter  







































Fig 3.23: NFAT4 is constitutively associated with the human αGSU promoter. 
Human-αGSU promoter 1.2 kb construct (1 µg) was transfected into 60 mm plate of αT3-1 cells. The cells 
were treated with GnRH (100 nM, 8 h) before harvest and fixed with formaldehyde and lysed. PIP was 
carried out using antibody to NFAT4. PCR analysis using specific primers on the promoter (A) and the 
vector backbone (B) were carried out on the input (lower panel) and the precipitated DNA (upper panel). 
All pull downs were carried out in duplicates, with and without the antibody.  
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In order to confirm whether NFAT regulates human αGSU promoter activity, the effects 
of dominant negative NFAT (dnNFAT) on the human αGSU promoter activity were 
tested in untreated and GnRH treated cells. This showed that over-expression of dnNFAT 
significantly reduced basal human αGSU promoter activity, but there was no obvious 
effect on the promoter response to GnRH, which remained elevated about 2.5 fold (Fig 
3.24).   
Fig 3.24: Effects of over-expression of dnNFAT on the human αGSU gene promoter activity. 
αT3-1 cells were transfected with 200 ng of human α-luc construct and some with 100-200 ng of dominant 
negative NFAT expression vector (dnNFAT). Some of the transfected cells were also exposed to GnRH 
(100 nM, 8 h). Luciferase assay was carried out and the levels of luciferase normalized to levels of Renilla; 
the results are expressed as fold induction over the human α-luc control-transfected cells without treatment. 
Statistical analysis (ANOVA followed by Bonferroni t-test) compared the mean values separately for 
groups with and without dnNFAT transfection. Means designated by the same letter are not significantly 
different (P>0.05). Additional analysis compared means for each treatment group with and without co-
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The above results reveal that NFAT4 and NFAT3 are associated with the human αGSU 
promoter. The sequence between -420 and -224 bp in human αGSU subunit promoter has 
previously been reported to mediate the promoter response to calcium influx (Holdstock 
et al., 1996). Analysis of this region revealed four consensus NFAT binding sites (Fig 
3.25). 
 














-67  gatcccagggcttagatgcaggtggaaacactctgctggtataaaagcaggtgaggactt 
-7        cattaact 
Fig 3.25: The consensus and putative NFAT binding sites between -420 and -224 bp in the human 
αGSU gene promoter. 
The human αGSU gene promoter sequence is from NCBI, Accession No. L05632. The four putative NFAT 
binding sites (5’-GGAAA-3’) are highlighted in blue and underlined. The putative TATAA sequence is 
highlighted in red and boxed, the PGBE element is highlighted in purple and underlined, the CRE element 
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In order to determine the roles for these sites in NFAT activation of the human αGSU 
promoter, site-directed mutagenesis was carried out. Luciferase assays demonstrated that 
mutation of the NFAT binding site at -360 bp decreased the basal human αGSU promoter 
activity, however, the promoter response to GnRH was not affected by mutation any of 










Fig 3.26: Effects of mutation of putative NFAT binding sites on the human αGSU gene promoter 
activity. 
αT3-1 cells were transfected with 200 ng of wild-type human α-luc construct, or the same construct after 
mutation of the four putative NFAT binding sites, α-Mut1, α-Mut2, α-Mut3 and α-Mut4, respectively. 
Some of the transfected cells were also exposed to GnRH (100 nM, 8 h). Luciferase assay was carried out 
and the levels of luciferase normalized to levels of Renilla; the results are expressed as fold induction over 
the human α-luc control-transfected cells without treatment. Statistical analysis (ANOVA followed by 
Bonferroni t-test) compared the mean values separately for groups with and without GnRH treatment. 
Means designated by the same letter are not significantly different (P>0.05). Additional analysis compared 
means for each treatment group with and without GnRH treatment; statistically different means are 
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3.4 Calcineurin plays a role in the GnRH-mediated derepression of the FSHβ gene 
in the immature gonadotrope 
 
3.4.1 Inhibition of calcineurin abolishes the GnRH derepression effects on the FSHβ 
gene 
Previous studies have shown that in the immature gonadotrope αT3-1 cells, a complex 
comprising several histone-deacetylases (HDACs) and co-repressors is associated with 
the FSHβ gene promoter to repress gene expression. GnRH overcomes this HDACs-
mediated repression of FSHβ, but the mechanisms remain unknown (Koh, 2004). RT-
PCR analysis in αT3-1 cells showed that FSHβ mRNA levels increased in response to 
GnRH treatment, but this effect was attenuated when combined with CsA treatment to 
inhibit calcineurin (Fig 3.27). The role of calcineurin in GnRH-mediated derepression of 










Fig 3.27: RT-PCR analysis of FSHβ mRNA levels in αT3-1 cells incubated with GnRH and/or CsA.  
αT3-1 cells were treated with CsA (10 µM, 30 min) before the application of GnRH (100 nM, 8 h). Total 
RNA was extracted for RT-PCR. Controls comprised untreated cells. The primers amplified a 476 bp DNA 
fragment of the FSHβ and a 261 bp DNA fragment of the α subunit cDNA. Amplification of a 150 bp 
fragment of the β-actin cDNA served as the control.  
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3.4.2 Nur77 and MEF2D activate the FSHβ gene  
In order to elucidate the mechanisms for calcineurin mediation of GnRH derepression of 
the FSHβ subunit gene; the mouse FSHβ promoter sequence was analyzed, and putative 
binding sites for two calcineurin targets, Nur77 and MEF2 were identified (Fig 3.28).  
 

















-60  acccagtaaatccacagggttttaagtttgtataaaagatgaggtgtaacttgactcagt 
 
Fig 3.28: The putative MEF2 and Nur77 binding sites on the 1kb promoter of the mouse FSHβ 
subunit gene. The mouse FSHβ subunit promoter sequence is from Ensembl ID. ENSMUSG00000027120. 
The putative Nur77 binding site (NBRE; 5’- AAAG(A/G)TCA-3’) are highlighted in red and underlined. 
The putative MEF2 binding site (MEF2 RE; 5’ -CT(A/T)(A/T)AAAT(A/G)(G/C)-3’) is highlighted in blue 
and underlined. 
 
In order to confirm whether Nur77 or MEF2 are involved in the derepression of FSHβ 
gene, MEF2A, MEF2D, and Nur77 expression vectors were constructed. RT-PCR 
analysis showed that over expression of Nur77 or MEF2D, but not MEF2A increased the 
FSHβ transcript levels, (Fig 3.29), while αGSU and the internal control β-actin mRNA 
NBRE 
MEF2 RE 
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levels remained unchanged. In addition, luciferase assays using the proximal 600 bp of 
mouse FSHβ promoter showed that over-expression of Nur77 increased FSHβ proximal 
promoter activity nearly 5 fold, while there is no obvious activation of the promoter 



























Fig 3.29: RT-PCR analysis of the effects of over-expression of various transcription factors on the 
gonadotropin gene mRNA levels in αT3-1 cells. 
αT3-1 cells in 6-well plate were transfected with MEF2A, MEF2D, or Nur77 expression vectors (1µg/well). 
After transfection for 40 h, total RNA was extracted for RT-PCR. Controls comprised untransfected cells 
The primers amplified a 476 bp DNA fragment of the FSHβ and a 261 bp DNA fragment of the α subunit 
cDNA. Amplification of a 150 bp fragment of the β-actin cDNA served as the control.  
 
   1           2            3          4                   5         6             7           8 
1-2. Control 
3-4. Over-expression of Nur77 
5-6. Over-expression of MEF2A 
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Fig 3.30: Effects of over-expression of various transcription factors on the FSHβ proximal promoter 
activity. 
αT3-1 cells were transfected with 200 ng of mouse FSHβ-luc construct or the control pGL3 basic vector, 
and 100 ng of MEF2A, MEF2D or Nur77 expression vectors. Luciferase assays were carried out and the 
levels of luciferase normalized to levels of Renilla; the results are expressed as fold induction over the 
mouse FSHβ-luc control-transfected cells. Statistical analysis (ANOVA followed by Bonferroni t-test) 
compared the mean values separately for groups pGL3 and pGL3-FSHβ constructs. Means designated by 




The above findings suggest that Nur77 and MEF2D activate FSHβ gene expression. The 
endogenous expression of Nur77 and MEF2 in the αT3-1 cells was then examined. RT-
PCR showed that the basic Nur77 mRNA level is very low, but its transcript levels 
significantly increased within 1 h GnRH exposure, which has also been shown by 
previous reports (Karkar, et al., 2003). However, GnRH induction of Nur77 was abated 
when combined with exposure to CsA, which indicates that GnRH induction of Nur77 
invloves calcineurin (Fig 3.31). MEF2 has four isoforms, named as MEF2A, B, C, and D. 
In αT3-1 cells, only MEF2A and MEF2D are expressed in the gonadotrope cell, and their 
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Fig 3.31: RT-PCR analysis of Nur77 mRNA levels in αT3-1 cells incubated with GnRH and/or CsA.  
αT3-1 cells were treated with CsA (10 µM, 30min) before the application of GnRH (100 nM, 1 h). Total 
RNA was extracted for RT-PCR. Controls comprised untreated cells. The primers amplified a 380 bp 























Fig 3.32: RT-PCR analysis of MEF2 mRNA levels in αT3-1 cells incubated with GnRH.  
αT3-1 cells were treated with GnRH (100 nM, 8 h). Total RNA was extracted for RT-PCR. Controls 
comprised untreated cells. The primers amplified the 1.5 kb full-length cDNA of the MEF2A and MEF2D. 
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3.4.3 The mechanism for Nur77 and MEF2D activation of the FSHβ gene 
In order to elucidate the mechanism for Nur77 and MEF2D activation of FSHβ gene, 
ChIP assay was carried out to determine whether Nur77 and MEF2D are directly 
associated with the FSHβ promoter. The results demonstrated that Nur77 is associated 
with the FSHβ promoter at basal and GnRH-stimulated conditions (Fig 3.33). ChIP assay 
using antisera that recognizes all the isoforms of MEF2, showed that MEF2 is also 
associated with the FSHβ promoter, with and without GnRH treatment (Fig 3.34).  
         
 














Figure 3.33: Nur77 is associated with the mouse FSHβ promoter. 
αT3-1 cells were treated with GnRH (100 nM, 2 h) before being harvested, fixed with formaldehyde and 
lysed. ChIP was carried out using antibody to Nur77. PCR analysis using specific primers to amplify a 500 
bp fragment of the mouse FSHβ promoter was carried out on the precipitated DNA (upper panel) and the 
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Figure 3.34: MEF2 is associated with the mouse FSHβ promoter. 
αT3-1 cells were treated with GnRH (100 nM, 2 h) before being harvested, fixed with formaldehyde and 
lysed. ChIP was carried out using antibody to MEF2. PCR analysis using gene specific primers to amplify a 
500 bp fragment of the mouse FSHβ promoter was carried out on the precipitated DNA (upper panel) and 
the input (lower panel). All pull downs were carried out in duplicates, with and without the antibody.  
 
3.4.4 CaMKs roles in mediating of GnRH derepression effects on the FSHβ gene 
One of the ways in which MEF2 can be transformed from a repressor to an activator of 
transcription, while associated with a promoter, is through phosphorylation of associated 
class II HDACs, and a previous study in our lab showed that GnRH treatment leads to 
export of these HDACs from the nucleus to the cytoplasm (unpublished data). CaMKI 
and IV phosphorylate class II HDACs, which allows them to interact with 14-3-3 proteins, 
leading to subsequent nuclear export (McKinsey et al., 2000). In this study, the 
possibility that CaMKI and CaMKIV are activated by GnRH was examined. Western 
analysis carried out in αT3-1 cells showed that p-CaMKI levels increased after GnRH 
treatment for 5 min, then continued to increase gradually until 1 h. However, p-CaMKIV, 
which was barely detectable, remained almost constant following GnRH treatment (Fig 
3.35). The roles of CaMKs in mediating GnRH derepression of the FSHβ gene in αT3-1 
cells were also investigated by using CaMK inhibitor KN-93. KN-93 was originally 
 Precipitated  
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- + - +
- - - - + + + +
- - + + - - + +  +MEF2 Ab 
 +GnRH  
- - + +  +GnRH  
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regarded as a CaMKII specific inhibitor (Sumi et al., 1991), but recent studies suggest 
that it competitively inhibits calmodulin binding to all CaMKs (Anderson et al., 1998). 
RT-PCR showed that KN-93 treatment inhibited GnRH induction of FSHβ transcript 
levels (Fig 3.36). These results confirmed that the ability of GnRH to overcome HDAC-

















Fig 3.35: CaMKI, but not CaMKIV is activated by GnRH in the αT3-1 cells. 
αT3-1 cells were cultured and exposed to GnRH for 0-1 h. The cells were lysed and the cell extract was run 
on 10 % SDS gel before Western analysis using antisera to p-CAMKI (upper panel), p-CaMKIV (middle 
panel), or GAPDH (lower panel) as control for protein loading. The apparent molecular weight of the target 



















Fig 3.36: RT-PCR analysis to investigate KN-93 effect on the gonadotropin gene mRNA levels in 
αT3-1 cells. 
αT3-1 cells were exposed to KN-93 (10 µM, 30min) before the application of GnRH (100 nM, 8 h). Total 
RNA was extracted for RT-PCR. Controls comprised untreated cells. The primers amplified a 476 bp DNA 
fragment of the FSHβ. Amplification of a 150 bp fragment of the β-actin cDNA served as the control. 
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CHAPTER 4   DISCUSSION  
 
4.1 Differential gene expression in gonadotropes 
 
4.1.1 Differential gene expression in the differentiating gonadotrope 
The αT3-1 and LβT2 cells represent two different stages of embryonic development of 
gonadotrope cells, and the β subunit genes are only expressed in LβT2 cells. However, 
transcription factors known to be crucial for β subunit gene expression are expressed in 
both cell types. In this study, in order to elucidate the novel mechanisms involved in β 
subunit expression, SSH was carried out to identify the genes whose expression levels are 
higher in LβT2 cells. A number of factors were identified and involved in RNA splicing, 
protein modification, microtubule organization, and ion transport in other cell contexts.  
 
To date, the differential gene expression in αT3-1 and LβT2 cells remains largely 
unknown. One previous study, using PCR differential display, identified a high mobility 
group (HMG)-like nuclear phosphoprotein known as p8, which has a higher expression 
levels in LβT2 cells than in αT3-1 cells (Quirk et al., 2003). Transfection of siRNA to 
knockout p8 expression in LβT2 cells diminished the LHβ gene expression and the LHβ 
promoter activity. However, over-expression of this protein neither induced LHβ 
expression in αT3-1 cells nor increased LHβ promoter activity in LβT2 cells. Therefore, 
this protein is necessary but not sufficient for LHβ expression, and probably functions to 
change the chromatin structure (Quirk et al., 2003).  
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Two-dimensional (2D) gel electrophoresis to compare the protein expression profiles 
between αT3-1 and LβT2 cells was also carried out in our lab, and a number of factors 
were identified (Feng, 2004; unpublished data). Interestingly, the tubulin beta 5 subunit 
identified in this study was also selected by 2-D gel electrophoresis, and RT-PCR has 
confirmed the higher expression levels for tubulin beta 5 in LβT2 cells (Feng, 2004; 
unpublished data). This tubulin isotype has been shown to express differentially during 
development (Lewis et al., 1985). Considering that tubulin is involved in a variety of 
cellular processes such as intracellular transportation, cell division and movement, the 
differential expression of this tubulin subunit may account for the different appearance in 
flagellar of the two cell lines. However, as a housekeeping protein, tubulin may not be 
directly involved in transcriptional regulation of β subunits. Furthermore, several proteins 
involved in RNA splicing regulation were identified by 2-D gel study as being 
differentially expressed in the cell lines (Feng, 2004; unpublished data), and this study, 
two regulators of RNA splicing were also identified: RNA binding motif protein 16 and 
RNA binding motif protein 15 B. Previous studies in our lab have shown that the splicing 
of several genes, including the gonadotropins, unlike in LβT2 cells, is not complete in the 
αT3-1 cells, which may be explained by these differentially expressed RNA splicing 
factors. Further studies need be carried out to confirm the differential expression of these 
genes in the two cell lines, and to investigate the possible functions of these factors in 
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4.1.2 Genes up-regulated following GnRH treatment in mature gonadotropes 
In order to examine the gene network program involved in mediating GnRH effects on 
the gonadotrope, SSH was utilized to identify the genes whose transcript levels were up-
regulated by GnRH on a genomic scale. The identified factors include genes that encode 
proteins involved in transcriptional regulation, cell metabolism, ion transport and 
apoptosis. Most of these identified factors have not previously been reported to mediate 
GnRH effects, however, RT-PCR or northern blot needs to be carried out to confirm the 
differential expression of these genes. 
 
A variety of signaling pathways are known to be activated by GnRH, however, only a 
limited number of nuclear GnRH targeted factors have been identified, and little is known 
concerning their roles in mediating GnRH signaling. The early response gene network 
controlled by GnRH has been investigated by several studies. Wurmbach et al., (2001), 
using focused cDNA array consisting of cDNA from 956 known genes combined with 
real-time PCR, reported that 26 genes were at-least two-fold up-regulated following 1 h 
exposure to GnRH in LβT2 cells. However, the expression of these genes returned to the 
basal levels or nearly basal levels within 3 h GnRH treatment (Wurmbach et al., 2001). 
Another report using an Affymetrix DNA microarray chip (Mu74av2), which represents 
approximately 12,400 mouse genes, was employed to analyze genes in LβT2 cells 
following GnRH treatment for 1 h and 24 h, and this showed that 27 genes were up-
regulated, and 18 genes were down-regulated following the 1 h GnRH treatment (Kakar 
et al., 2003). More recently, in order to examine the mechanisms regulating biosynthesis 
and secretion of FSH, genes that are regulated by activin, alone or in combination with 
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GnRH were investigated by microarray analysis using the same screen Affymetrix 
Mu74av2 mouse Gene Chip (Mazhawidza et al., 2006). The factors identified as 
responding to GnRH from these studies include those involved in transcriptional 
regulation: Egr-1, Egr-2, Nr4a1 (Nur77), Kruppel-like factor 4 (Klf4), ATF3, c-fos and c-
jun; factors involved in signal transduction: regulator of G-protein signaling 2 (Rgs2), I
B, and Peroid (Per1); a calcium channel regulator, gem; and proteins contributing to 














Fig 4.1: The identified transcripts up-regulated by GnRH in LβT2 cells.  
All real-time PCR-confirmed microarray-identified genes regulated by GnRH (100 nM, 1 h) in LβT2 cells 
are shown. abbreviations: LRG21: activating transcription factor 3 (Atf3);  Klf4, Kruppel-like factor 4; 
Nr4a1, nuclear receptor subfamily 4, group A, member 1 (Nur77); Egr2, early growth response 2; TSC22, 
TGF-beta stimulated clone-22; Nrf2, NF-E2 related factor 2; Ier2, immediate early response 2; Rgs2, 
regulator of G-protein signaling 2;  MKP1, MAP kinase phosphatase 1; PRL1, protein tyrosine phosphatase 
1. Adapted from Wurmbach et al., 2001. 
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Among the factors identified in the subtracted library, was the previously identified factor 
Rgs2. Rgs2 is a GTPase-activating protein that down-regulates the activity of Gαq (De 
Vries and Gist Farquhar, 1999), the major G-protein utilized by the GnRH receptor 
(Grosse et al., 2000). The induction of Rgs2 by GnRH is likely involved in 
desensitization of GnRH receptor signaling. In addition, the identified TPA-induced 
TIS11, an unknown zinc finger protein, was also found in the previous two reports and 
may be involved in transcriptional regulation (Kakar et al., 2003; Mazhawidza et al., 
2006). Interestingly, solute carrier family member Slc6a4 was previously identified to be 
up-regulated by GnRH (Kakar et al., 2003), and this study, another member of solute 
carrier family 6, member 6 (Slc6a6) was also identified. Slc6a6 has been shown to be up-
regulated in developing neurons from mouse cerebral cortex (Fujita et al., 2006). 
Members of the solute carrier family (SLC) play an important role in the efflux transport, 
especially for organic anions (Hagenbuch and Meier, 2004). Up-regulation of SLC ion 
transporters will lead to a more active metabolic rate. 
 
The previously characterized early response genes, such as Egr-1, Egr-2 and Nur77 were 
not identified in this study, which is likely due to the fact that the transcripts of these 
early response factors already return to the basal levels after 8 h GnRH treatment 
(Wurmbach et al., 2001). Among the factors identified as being up-regulated by GnRH, 
the induction of ubc4 and calcineurin catalytic subunit A by GnRH was confirmed at both 
mRNA and protein levels. Furthermore, functional studies indicated that they are 
involved in mediating GnRH effects on the gonadotropin genes. 
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4.2 Ubc4 regulation of LHβ gene expression through increasing ERα transactivation 
In this study, a novel form of cross-talk between two hormonally-induced signaling 
pathways was revealed, in which GnRH increases ERα degradation and transactivation of 
the LHβ gene, apparently through stimulation of ubc4 expression. It was further 
demonstrated that the stimulatory effect of ERα on LHβ expression is mediated through 
interactions with other regulatory transcription factors on the proximal promoter, without 
necessarily requiring an ERE.  
 
The finding that GnRH up-regulates the transcript levels of ubc4, to our knowledge, is the 
first report of an ubiquitin conjugating enzyme being directly stimulated by a cell-
membrane bound hormone. GnRH was previously implicated in stimulating 
ubiquitylation of inositol trisphosphate receptors in αT3-1 cells, which was dependent on 
intracellular Ca2+, although the molecular mechanisms involved were not described 
(Wojcikiewicz et al., 2003). The GnRH-stimulated signaling pathway specifically leading 
to ubc4 transcription is still not elucidated, and requires further experiments, such as 
blocking a certain signaling pathway to check ubc4 expression in response to GnRH, or 
analyzing the ubc4 promoter to identify the putative transcription factor binding sites. 
Notably, however, a recent report showed that ERα is degraded in MCF-7 cells through 
activation of PKC, but not MAPK (Marsaud et al., 2003), both of which are activated in 
the GnRH signaling pathway (Naor et al., 2000).  
 
Use of siRNA to knockdown ubc4 revealed that ubc4 is involved in the GnRH-induced 
ERα degradation and ERα transactivation of LHβ gene. This was also the case for ubc4-, 
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but not ubc2-mediated ubiquitylation of various rat proteins in which immunodepletion 
decreased and ubc4 administration increased levels of the ubiquitylated proteins 
(Rajapurohitam et al., 2002). The idea that ubc4 ubiquitylates and degrades ERα and that 
this regulates its transactivation of the LHβ gene, concur with a recent report that ubc4 
(ubcH5) is required for ligand-mediated ERα transactivation of the pS2 promoter (Perissi 
et al., 2004). That report further suggested that TBL1 and TBLR1 are the specific adaptor 
proteins responsible for ubc4 recruitment which was essential for transactivation by all 
nuclear receptors tested, although additional more specific E2 enzymes were also 
recruited: ERα requiring specifically ubcH7, which may be recruited through interactions 
with SRC-1 (Perissi et al., 2004; Verma et al., 2004). An earlier study demonstrated that 
the incubation of ERα with an E1 enzyme together with both ubc4 and ubcH7, led to 
degradation of ERα, but not of progesterone or thyroid hormone receptors (Nawaz et al., 
1999). Although some E2 enzymes, including ubc4, are able to ubiquitylate the substrate 
directly, the E3 enzymes are thought to provide a crucial role in substrate recognition 
(Conaway et al., 2002; Weissman, 2001). ERα is known to interact with E6AP, which 
accepts ubiquitin from ubc4 and was associated with ERα in re-ChIP experiments (Anan 
et al., 1998; Reid et al., 2003). Moreover, gene knock-out of E6AP revealed reproductive 
deficient animals with small gonads. However the females did cycle and even produced 
liters (Smith et al., 2002). Given that estrogen-mediated regulation of cyclical circulating 
LH levels is crucial to ovulation, it is unlikely that E6AP has a role in regulating LHβ 
production. ERα has been noted to associate with a variety of additional E3 ligases: at the 
pS2 promoter ERα associates with MDM2 and Rpt6, while other studies have shown 
ubiquitylation and degradation of ERα are mediated through the NEDD8 pathway (Fan et 
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al., 2003). NEDD8 enhances ubiquitylation by the SCF (Skp1, Cul-1, ROC1 and F-box 
protein) E3 complex and specifically increases recruitment of ubc4, so increasing 
polyubiquitylation (Kawakami et al., 2001; Strack et al., 2000).  
 
Western analysis studies carried out in our lab revealed that GnRH enhances primarily 
monoubiquitylated ERα levels, suggesting that this might be a step distinct from 
subsequent polyubiquitylation and proteasomal degradation (Feng, 2004; Luo et al., 
2005). If this were not the case, at least the di-ubiquitylated ERα would be observed 
before further chain elongation and recognition by the proteasome. Thus it is proposed 
that the actions of GnRH-induced ubc4 comprise a pre-requisite to subsequent 
degradation by additional receptor-specific E2 enzymes, possibly reflecting 
differentially-regulated mono- and polyubiquitylation. The molecular mechanisms 
involved in differentiating between mono- and polyubiquitylation have yet to be defined 
and although a recent report suggested the concentration of the E3 ligase could be the 
determinant (Li et al., 2003), the latter may well also require additional enzymes, such as 
E4 ligases involved in promoting chain assembly, or the inhibition of negative regulators 
(Koegl et al., 1999; Ortolan et al., 2000). 
 
The transfection studies indicate that an ERE is not required for ERα transactivation of 
the csLHβ promoter. Further site-directed mutagenesis showed that for the csLHβ gene 
promoter, Sf-1 RE, but not Pitx1 RE is crucial for ERα transactivation. However, for the 
rLHβ gene promoter, both Sf-1 and Pitx1 REs are crucial for ERα transactivation. 
Furthermore, the PIP assay in our lab confirmed that the recruitment of ERα to the LHβ 
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gene promoter requires the Sf-1 RE on both csLHβ and rLHβ gene promoters (Koh, 2004; 
Luo et al., 2005). The fact that the rLHβ gene promoter is unresponsive to the liganded 
ERα unless Sf-1 and Pitx1 are over expressed indicates a co-operative mechanism of ERα 
recruitment for activation of mammalian LHβ genes requiring also activation of these 
other transcription factors.  
 
Mammalian two-hybrid assays indicate that ERα dimerization and its interactions with 
Pitx1 and Sf-1 appear to increase when ubc4 is over-expressed, however, these proteins 
do not contain any of the domains known to bind ubiquitin (Di Fiore et al., 2003; Schnell 
and Hicke, 2003; Weissman, 2001). It is possible that the increased transactivation of the 
reporter gene occurs as a result of increased ERα interaction with a common co-activator 
complex. This is feasible given that a number of coactivators have been shown to contain 
ubiquitin recognition domains, while the TBLR1-ubc4 complex was proposed to serve 
specifically to facilitate removal of co-repressors and help recruit both the ubiquitin/19S 
proteasome and the coactivator complex (Brower et al., 2002; Grossman et al., 2003; 
Perissi et al., 2004). UbcH7 was recently also reported to function as a steroid hormone 
coactivator, acting through SRC-1 (Verma et al., 2004). Further studies will be required 
to understand whether this increased interaction is a direct consequence of the ERα 
ubiquitylation or a result of the recruitment of additional bridging molecules to facilitate 
the increased association with the LHβ gene promoter. Interestingly, the ring finger E3, 
SNURF, co-precipitates with Sf-1 and specifically enhances LHβ gene transcription. The 
proposed mechanism for this enhancement was through repressing suppression by 
androgen receptor which inhibits transcription of this gene through interactions with Sf-1 
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(Curtin et al., 2004). However SNURF, which also serves as a coactivator for ERα, 
accepts ubiquitin from ubc4 and is up-regulated by estrogen exposure (Hakli et al., 2004; 
Hirvonen-Santti et al., 2004; Saville et al., 2002). It is plausible, therefore, that the effects 
of SNURF on LHβ gene transcription are in fact through ERα ubiquitylation whose 
increased association with the pre-initiation complex and, specifically Pitx1, facilitates 
competition of the latter with AR for binding to the putative ligand binding domain of Sf-
1 (Tremblay et al., 1999).  
 
ChIP assays carried out in our lab showed that ERα is associated with the promoter for 
longer cycles following the GnRH treatment (Koh, 2004; Luo et al., 2005). GnRH 
exposure also increases the amount of LHβ gene promoter associated with the ERα (Koh, 
2004; Luo et al., 2005), presumably as a result of increase in its affinity, or stronger 
interaction with the gene-specific and pre-initiation transcriptional complexes. In addition, 
ubc4 over-expression increases ERα association with the promoter and increases 
synergistic actions of the three transcription factors on LHβ promoter activity. 
Conversely, blocking ubc4 expression reduces the ability of ERα to associate with the 
promoter, and also virtually abolishes the GnRH effect on promoter activity (Koh, 2004; 
Luo et al., 2005).  
 
The crosstalk between GnRH and E2 on LHβ gene expression have been shown and 
explained by a number of mechanisms, some of which involve increasing the 
gonadotropes sensitivity to GnRH by E2. These include E2/estrogen receptor (ER) effects 
on Egr-1, calcium influx and on MAPK (Colin and Jameson, 1998; Cowley et al., 1999; 
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de Jager et al., 2001; Pratt et al., 1998). Conversely, the effects of ERα on estrogen 
responsive promoters are enhanced by GnRH, possibly involving MAPK-
phosphorylation of ERα which facilitates protein-protein interactions and transactivation, 
even in the absence of a ligand (Demay et al., 2001; Lu et al., 2002; Metivier et al., 2002). 
This study has shown that ERα activity is modified locally at the gonadotrope by GnRH-
mediated ubiquitylation and degradation, which adds a novel dimension to the molecular 
mechanisms regulating gonadotropin synthesis, and a new form of cross-talk between 
GnRH and E2 stimulated pathways. The possible model for the role of GnRH-induced 
activation of ubc4 and ERα ubiquitylation in the activation of LHβ gene transcription is 






























Fig 4.2:  Model for the role of GnRH-induced activation of ubc4 and ERα ubiquitylation in the 
activation of LHβ gene transcription.  
GnRH activates formation of the tripartite complex of factors comprising Sf-1, Pitx1 and Egr1 (Brown and 
McNeilly, 1999; Dorn et al., 1999; Tremblay and Drouin, 1999), which bind respective REs on the mammalian 
LHβ gene promoter (distal Sf-1 and Egr-1 REs are not shown). 1. At the same time, GnRH stimulates transcription 
of ubc4 which leads to ERα mono-ubiquitylation and subsequent recruitment to the DNA bound complex. 
Transcription is activated as a result of recruitment of additional coactivators (black shapes) and the general 
transcription machinery. 2. Transcriptional activation results in recruitment of additional E2 enzymes, E3 ligases 
and E4 chain elongation factors to the complex, leading to ERα polyubiquitylation, removal from the LHβ gene 
promoter and degradation by the proteasome. 3. The LHβ promoter is available for subsequent activation by ERα 
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4.3 Calcineurin is involved in GnRH-stimulated human αGSU promoter activity 
The current study has revealed that GnRH increases calcineurin catalytic subunit A (CnA) 
expression levels in the gonadotrope-derived cells, and that calcineurin plays an 
important role in regulating both basal and GnRH stimulated human αGSU promoter 
activity. Calcineurin, a Ca2+ and CaM-dependent serine/threonine protein phosphatase, 
consists of a 58-64-kDa catalytic subunit calcineurin A (CnA), and a 19-kDa Ca2+-
binding regulatory subunit calcineurin B (CnB; Klee and Krinks, 1978). CnA includes 
three regulatory domains at its C terminus, which have been identified as the CnB 
binding domain (Clipstone et al., 1994), the CaM-binding domain (Guerini et al., 1992; 
Kincaid et al., 1988) and the "autoinhibitory" domain (Hashimoto et al., 1990; Perrino et 
al., 1995; Fig 4.3). The autoinhibitory domain binds in the active site in the absence of 
Ca2+/CaM and inhibits the calcineurin phosphatase activity (Kissinger et al., 1995). In 
signaling pathways that lead to a rise in intracellular Ca2+, Ca2+ binding leads to 
conformational change of CaM, which binds to the CaM-binding domain of calcineurin, 
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Fig 4.3: Functional domains and crystal structure of calcineurin A (CnA).   
(A). Schematic representation of functional domains of CnA. Abbreviations: CaM, calmodulin; CNB, 
calcineurin B; AI, autoinhibitory. (B). Ribbon representation of the crystal structure of truncated 
calcineurin complexed with FKBP12-FK506. Calcineurin A is shown in red and calcineurin B in purple 
with myristic acid covalently linked to the N-terminal glycine shown in pink. Iron and zinc in the active site 
are shown as yellow and green spheres respectively, and the bound phosphate is shown in purple. The four 
Ca2+ in the calcineurin B sites are shown as pink spheres. FKBP12 is shown in green, and FK506 (yellow) 
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CnA expression levels increased following GnRH treatment in gonadotrope-derived cells, 
through a mechanism that has yet to be identified. One report has shown that in cardiac 
myocytes, CnA mRNA and protein levels increased in response to hypertrophic stimuli, 
through a positive feedback mechanism involving NFAT and GATA transcription factors, 
which activates the CnA promoter (Oka et al., 2005). Whether CnA expression levels 
increase following GnRH treatment in gonadotrope through a similar mechanism needs 
to be investigated. 
 
Calcineurin inhibitor, CsA, decreased the basal human αGSU promoter activity and 
significantly reduced promoter response to GnRH. The mechanism through which CsA 
inhibits calcineurin involves formation of a complex with a specific cyclophilin, which 
binds and inhibits the catalytic subunit activity of calcineurin (Clipstone and Crabtree, 
1993; Liu et al., 1991; Schreiber, 1992). In addition, the siRNA targeting CnA also 
reduced basal and GnRH stimulated human αGSU promoter activity. These findings 
suggest that calcineurin serves as a positive signal necessary for both basal and GnRH 
stimulated human αGSU subunit gene expression. Over-expression of calcineurin 
increased the human αGSU promoter activity nearly 3 fold, however, a synergistic effect 
of GnRH and over-expression of calcineurin on the human αGSU promoter activity was 
not observed, which is probably due to the maximal activation of calcineurin in the 
GnRH signaling pathway. 
 
Compared to the well-explored kinases, the functions and mechanisms of phosphatases in 
mediating GnRH signals to gonadotropin genes are less well understood. One report 
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showed that the inhibitors of protein phosphatase type 1 (PP1) and 2A (PP2A), okadaic 
acid and calyculin A, inhibited the GnRH stimulated LH release, which suggests that PP1 
and PP2A are involved in mediating GnRH effects on LH release (Marantz et al., 1995). 
It also has been shown that GnRH induces MAPK phosphatase 2 (MKP-2) expression in 
both αT3-1 and rat primary pituitary cells (Roberson et al., 1995). Further 
pharmacological studies indicated that MKP-2 activation requires the ERK cascade, 
while over-expression studies using the JNK anchoring protein JIP-1 implicated a role for 
JNK in MKP-2 activation (Zhang et al., 2001). Additional attempts to identify genes 
regulated by GnRH in a genomic scale by microarray revealed that nuclear protein 
tyrosine phosphatase (PRL-1) and MAP kinase phosphatase 1 (MKP-1) transcription 
levels were also up-regulated by GnRH (Wurmbach et al., 2001). The functions of these 
phosphatases in the GnRH signaling pathway remain to be elucidated. Two possible roles 
have been suggested: one is that GnRH stimulation of gonadotropin genes needs a 
continual phosphorylation/dephosphorylation cycle of key substrates to avoid 
desensitization to the GnRH signal, such as the G protein-coupled GnRHR (Marantz et 
al., 1995). The other suggests an opposite model, in which phosphatase activation down-
regulates the magnitude or duration of GnRH signaling through dephosphorylating and 
inactivating the kinases (Zhang et al., 2001).  
 
In order to examine the mechanism involved in calcineurin regulation of human αGSU 
gene, the effects of the most extensively studied calcineurin target, NFAT, were 
investigated. NFAT was first identified in T cells as a rapidly inducible nuclear factor 
binding to the human IL-2 promoter (Shaw et al., 1988). According to differences in the 
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sequence and function domains, four NFAT isoforms named as NFAT1 (NFATp or 
NFATc2), NFAT2 (NFATc or NFATc1), NFAT3 (NFATc4) and NFAT4 (NFATc3) 
have been identified (Ho et al., 1995; Hoey et al., 1995; Jain et al., 1993; Northrop et al., 
1994). NFAT is comprised of the N- and C-terminal transactivation domains (TADs), the 
DNA-binding domain (DBD; Jain et al., 1995) and the NFAT homology region (NHR; 
Luo et al., 1996a; Fig 4.4). The DBD and NHR are highly conserved within the known 
NFAT isoforms. The DBD domain is involved in binding DNA and interaction with other 
transcription factors, such as AP-1 (Chen et al., 1998). The NHR defines a calcineurin-
activated regulatory domain that binds calcineurin, and is dephosphorylated when 
calcineurin is activated, and controls the calcineurin regulated nuclear translocation of 
NFAT (Luo et al., 1996b). However, notably, apart from NFAT, calcineurin is also able 
to target other transcription factors through similar actions, including casein, Tcnp1, 
synapsin 1, and transcription factor Elk-1(Dawson et al., 1993; Gaestel et al., 1992; 
Sugimoto et al., 1997). For example, in yeast, calcineurin dephosphorylates the 
transcription factor Tcn1p and translocates it to the nucleus. Tcnp1 is required for 
induction of PMC1, PMR1, PMR2A, and FKS2 genes, which confer tolerance to high 
levels of Ca2+, Mn2+, Na+, and to cell wall damage, respectively (Matheos et al., 1997; 
Stathopoulos and Cyert, 1997). Calcineurin also dephosphorylates dopamine-and cAMP-
regulated phosphoprotein (DARPP-32), which is responsible for the opposite effects of 
glutamate and cAMP on neuronal excitability in striatal and hippocampal neurons 
(Halpain et al., 1990).  
 
 




Fig 4.4: Schematic representation of functional domains of murine NFAT1.  
NFAT is composed of a N-terminal transactivation domain (TAD), the NFAT homology region (NHR), 
which binds to calcineurin (Cn) and is found only in NFAT family proteins, the DNA-binding domain 
(DBD) for DNA-binding and C-terminal transactivation domain TAD (Rao et al., 1997). 
 
 
A combination of PKC and calcium influx induces human αGSU promoter activity in 
αT3-1 cells, which is consistent with previous reports, although the downstream factors 
remain to be fully characterized (Fowkes et al., 2003; Fowkes et al., 2002; Holdstock et 
al., 1996; Kay et al., 1994). Over-expression of constitutively active calcineurin (CA-
calcineurin) activates the human αGSU promoter activity in synergy with PKC and 
calcium (activated by PMA+ionomycin treatment), which suggests the crosstalk between 
calcineurin-regulated and PMA/Io triggered signaling pathways in induction of human 
αGSU gene. Such crosstalk may be mediated through interactions of their downstream 
factors, and it is known that NFAT usually forms a composite complex with other 
transcription factors to activate its target gene (Fig 4.5). For example, in T lympocytes, 
calcineurin dephosphorylates and translocates NFAT to the nucleus, which activates the 
interleukin-2 (IL-2) gene expression in synergy with AP-1 (Jain et al., 1993). In skeletal 
myocyte hypertrophy, calcineurin activates NFAT2, which acts in synergy with GATA2 
to activate the target gene expression (Musaro et al., 1999).  
 












Fig 4.5: Signal transduction by Ca2+, calcineurin and NFAT in lymphocytes, cardiac valves and 
cardiomyocytes. 
The red arrow indicates inhibition of the signaling pathway. NFATn is used to indicate transcription factors, 
such as AP1 and GATA4, and other yet to be-identified transcription factors that act together with nuclear 
NF-ATc to activate transcription. The term NF-AT kinases is used for the group of kinases that either 
oppose calcineurin’s actions or actually regulate export of the protein. Abbreviations used: CpH, 
cyclophilin; CRAC, calcium release-activated current (Crabtree, 1999). 
 
 
Western analysis revealed that GnRH activates NFAT3, which is calcineurin-dependent. 
Although NFAT4 protein level is not altered by GnRH, its activity in αT3-1 cells is also 
calcineurin-dependent. PIP assay indicated that NFAT3 is associated with the human 
αGSU promoter following GnRH treatment, while NFAT4 is constitutively associated 
with the promoter under both basal and GnRH-stimulated conditions. These results 
suggest that calcineurin regulates both basal and GnRH-stimulated human αGSU 
promoter activity, which may through activation of NFAT4 and NFAT3, respectively. 
However, over-expression of dominant negative NFAT (dnNFAT) only leads to a 
significant decrease in basal human αGSU promoter activity. A previous report showed 
over-expression of this dnNFAT (Section 2.2.2) downregulates NFAT1, 2 and 4-
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dependent transactivation, however, the effect on NFAT3 is not obvious (Chow et al., 
1999); this may explain why over-expression of dnNFAT did not affect promoter 
response to GnRH. Use of siRNA to knock down NFAT3 specifically could be carried 
out in future to confirm its roles in mediating the GnRH effect.  
 
Site-directed mutagenesis implicated that the NFAT site located at -360 bp may be 
responsible for NFAT4 association with the human αGSU promoter and its effects on the 
basal promoter acivity, while mutation any one of the consensus NFAT binding sites did 
not affect GnRH induction of the human αGSU promoter activity. Considering the 
possible compensatory effects between these sites, mutation of all of these sites in the 
same construct should be carried out to confirm these results. In addition, it is possible 
that NFAT interacts with other DNA binding factors to associate with the promoter.  
 
In summary, this study showed that calcineurin mediates both basal and GnRH 
stimulated human αGSU promoter activity. Calcineurin effect is likely to be transduced 
by its downstream transcription factors NFAT3 and 4. Based on the known signaling 
pathways of GnRH, activation of calcineurin may involve activation of PKC pathway and 
elevation of the intracellular Ca2+ levels; which is further enhanced by influx from the 
extracellular milieu. Ca2+ influx induces calmodulin, which activates calcineurin activity 
and its downstream NFAT transcription factors. As opposed to NFAT4, which is may 
involved in basal human αGSU promoter activity, NFAT3 is associated with the human 
αGSU promoter only after GnRH treatment, and possibly mediates GnRH effects on the 
human αGSU promoter. The synergistic effect between PKC and calcineurin in activation 
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of the human αGSU promoter are likely through NFAT interactions with other PKC 
activated transcription factors, such as possibly c-jun. Phosphorylation by PKC increased 
the transactivation activity of c-jun (Su and Karin, 1996), which binds the CRE element 
(-146 to-111 bp) in the human αGSU promoter in αT3-1 cells to activate the promoter 
activity when over-expressed (Jorgensen and Nilson, 2001). The possible model for the 
role of calcineurin and NFATs in regulating human αGSU promoter activity is shown in 















































Fig 4.6: Possible model for the role of calcineurin and NFATs in regulating human αGSU promoter 
activity. 
GnRH binding to its receptor on the plasma membrane activates the PKC pathway and elevates the 
intracellular Ca2+ levels. The intracellular Ca2+ levels activate calmodulin-dependent calcineurin. As 
opposed to NFAT4, which is constitutively associated with the human αGSU promoter, NFAT3 is activated 
and associated with the promoter only after GnRH treatment. These NFATs may interact with NFATn to 
activate human αGSU promoter activity synergistically. NFATn is used to indicate transcription factors that 
are activated by PKC and act together with nuclear NFAT to activate transcription. Abbreviations: CaM, 
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4.4 The role of calcineurin in GnRH-mediated derepression of the FSHβ gene in 
immature gonadotropes  
Previous studies have shown that in the immature gonadotrope αT3-1 cells, a set of 
HDACs and co-repressors are associated with the mouse FSHβ promoter to repress gene 
expression, and that GnRH overcomes this repression, however, the mechanisms 
involved were unknown (Koh, 2004). This study revealed the roles of calcineurin in the 
GnRH derepession of FSHβ in αT3-1 cells, which is transduced by two calcineurin 
targets Nur77 and MEF2D.   
 
Over-expression of Nur77 increased the mouse FSHβ transcript levels and the mouse 
FSHβ promoter activity. A member of steroid/thyroid hormone nuclear receptor 
superfamily (Baniahmad and Tsai, 1993; Freedman and Luisi, 1993), Nur77 is composed 
of a N-terminal transactivation domain, a DNA-binding domain (DBD), and a C-terminal 



















Fig 4.7: A diagram of Nur77 functional domains.  
The highly conserved DNA binding domain (DBD) includes two zinc-fingers, and four conserved motifs P-, 
D-, T- A-boxes that are responsible for the specific DNA binding. Abbreviations: C, carboxyl terminal; 
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RT-PCR revealed that Nur77 transcript levels are increased by GnRH, which is 
consistent with the  previous reports (Kakar et al., 2003; Wurmbach et al., 2001). As an 
immediate response gene, Nur77 expression can be induced in a wide variety of cell 
types. In immature thymocytes and T-cells, Nur77 expression is induced following T-cell 
receptor (TCR) activation (Liu et al., 1994; Woronicz et al., 1994). The mechanism 
involves calcineurin activation of NFAT that forms a ternary complex with MEF2D and 
p300 to activate the Nur77 promoter (Woronicz et al., 1995; Youn et al., 2000). In this 
study, use of CsA suggested that in the gonadotrope cells, Nur77 induction by GnRH is 
also calcineurin-dependent.  
 
Also in the pituitary, corticotropin releasing hormone (CRH) induces Nur77 expression in 
the corticotropes, which stimulates the synthesis of pro-opiomelanocortin (POMC), the 
precursor protein containing adrenocorticotrophic hormone (ACTH) peptide. The Nur77 
binds the Nur77 binding response element (NBRE) on the POMC promoter and activates 
the gene expression (Philips et al., 1997). In the gonadotrope cells, the roles for Nur77 in 
mediating GnRH effects have not yet been identified, although one previous report 
showed that Nur77 binds to the GnRH-R promoter with an inhibitory effect in αT3-1 
cells (Sadie et al., 2003).  
 
Notably, the basic level of Nur77 in αT3-1 cells is low, but ChIP results showed that 
Nur77 is associated with the mouse FSHβ promoter at both basal and GnRH-stimulated 
conditions. It is possible that apart from inducing its expression, GnRH also regulates 
Nur77 activity by post-translational modification. It has been reported that 
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phosphorylation of Ser105 by ERK1/2 affects Nur77 localization (Katagiri et al., 2000), 
while phosphorylation of Ser354 by JNK or Akt has been suggested to reduce Nur77 
DNA-binding and transactivation functions (Katagiri et al., 1997; Pekarsky et al., 2001). 
Some of these kinases have been shown to be activated by GnRH; their possible roles in 
GnRH alteration of Nur77 function would need further investigation.  
 
Nur77 activation of target genes usually involves binding as a monomer to the NBRE, 
which contains the hexanucleotide (5'-AGGTCA-3'), and two A residues preceding this 
hexanucleotide (Wilson et al., 1993). In addition, Nur77 also binds the target gene 
promoter as a homodimer or heterodimer with the retinoid X receptor (Perlmann et al., 
1995; Philips et al., 1997). In this study, a consensus NBRE on the FSHβ promoter was 
identified, although site-directed mutagenesis needs to be carried out to confirm its 
function. 
 
The above studies suggest that Nur77 activates the mouse FSHβ gene. Notably, Nur77 
knockout mice were produced, which developed normally with no reported changes in 
physiological function (Lee et al., 1995). Nur77 belongs to the Nur77 protein subfamily, 
which contains two other nuclear receptors, Nurr1 (Not 1) and NOR-1 (MINOR) (Hazel 
et al., 1988; Hedvat and Irving, 1995; Mages et al., 1994). Considering the similarity in 
the expression and DNA binding affinities for Nur77 and Nurr1 (and possibly NOR-1), it 
is possible that the same target genes may be regulated in a compensatory manner by 
other family members in the absence of Nur77. Creation of mice with gene knockout of 
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combinations of Nur77 subfamily members would allow examination of Nur77 
physiological functions. 
 
Over-expression of MEF2D also increased the mouse FSHβ transcript levels. An 
integrator of calcium signals, MEF2 is involved in diverse calcium signaling pathways 
that control cell division, differentiation and death. In muscle cells, MEF2 binds to the 
promoters of the majority of muscle-specific gene, and  interacts with members of the 
MyoD family to activate skeletal muscle differentiation (Black and Olson, 1998). MEF2 
also activates the cell-cycle regulator, c-jun, in response to signals from multiple cell 
surface receptors binding, including G-protein-coupled receptors (Coso et al., 1997; Han 
and Prywes, 1995). MEF2 factors usually include a N-terminal MADS domain, which 
mediates dimerization and binding to the DNA sequence CTA(A/T)4TAG/A, an adjacent 
MEF2-specific domain, which influences DNA-binding affinity and cofactor interactions, 
and a C-terminal transactivation domain, which is required for MEF2 transactivation 
activity (Black and Olson, 1998). Similar to other MADS domain proteins, MEF2 factors 
associate with a variety of transcriptional cofactors to control specific sets of downstream 
target genes. A summary of MEF2 functional domains and cofactor interactions is shown 












Fig 4.8: MEF2 structure and interaction partners.  




In contrast to Nur77, MEF2 transcription levels only slightly increased following GnRH 
treatment. Previous studies suggested that activation of MEF2 factors is not through 
increasing their expression levels, but rather through post-translational modification or 
affecting MEF2 protein-protein interactions, and this can convert MEF2 from a repressor 
to an activator. It has been reported that in unstimulated T cells, class II HDACs, 
including HDACs -4, -5 , -7 and -9 interact with  the MADS/MEF2 domains of all MEF2 
family members. This interaction does not affect MEF2 DNA-binding activity, but results 
in recruitment of HDACs to MEF2-dependent gene regulatory regions and repression of 
the target gene expression (McKinsey et al., 2001; Zhou et al., 2001; Blaeser et al., 2000; 
Esau et al., 2001; Liu et al., 2001). MEF2 can be activated by calcineurin, involving the 
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dephosphorylation of MEF2, which allows it to bind and stimulate the target gene 
transcription (Mao and Wiedmann, 1999). Calcineurin also disrupts MEF2–Cabin-
HDACs complexes (Youn and Liu, 2000; Fig 4.9).  
 
Fig 4.9: Three calcineurin-dependent mechanisms for regulation of MEF2 activity.  
(a) Recruitment of NFAT–p300 complexes to MEF2 target elements. (b) Stabilization of MEF2 protein. In 
depolarized neurons, calcineurin dephosphorylates MEF2. Unphosphorylated MEF2 binds target gene 
regulatory elements via its N-terminal MADS/MEF2 domains and stimulates transcription via its C-
terminal transactivation domain (TAD). (c) Targeting MEF2–Cabin complexes. In T lymphocytes, MEF2 
associates with Cabin, and HDACs -1 and -2 via the mSin3 co-repressor, resulting in repression of MEF2 
target gene transcription. In response to increased intracellular calcium, MEF2 associates with the NFAT–
p300 complexes and activate target gene expression. Adapted from McKinsey et al., 2002. 
  138  
CaMKI and CaMKIV can activate MEF2 through phosphorylation of the associated 
HDACs -4, -5, -7 and -9, causing their export from the nucleus to the cytoplasm 
(McKinsey et al., 2000; Miska et al., 2001). The current study showed that MEF2D is 
associated with the mouse FSHβ promoter at both basal and GnRH-stimulated conditions. 
Given that calcineurin and CaMKI are activated by GnRH, and previous studies in our 
lab showed that GnRH treatment leads to derepression of the FSHβ gene expression and 
nuclear export of HDACs 4, 5, 7 (unpublished data), it is likely that MEF2D is associated 
with the FSHβ promoter and interacts with HDACs at basal conditions, and that GnRH 
causes release of the HDACs from MEF2D, so allowing it to interact with co-activators 
to activate the FSHβ gene expression. In addition, MEF2 is also reported to be activated 
by p38, which phosphorylates residues in the transcriptional activation domain of MEF2, 
resulting in enhanced MEF2 activity (Han et al., 1997; Han and Molkentin, 2000). 
Activation of p38 by GnRH has been reported previously (Roberson et al., 1999), and its 
role in MEF2D activation should be verified by checking the phosphorylated MEF2 
protein levels.  
 
In summary, this study indicated that the actions of GnRH to derepress the FSHβ gene in 
the immature gonadotrope cells involves calcineurin targeted Nur77 and MEF2D. The 
possible mechanism involves CaMKI mediated phosphorylation and export of class II 
HDACs associated with the FSHβ gene promoter through MEF2D, while GnRH 
activated calcineurin may also enhance MEF2D interaction with co-activators to activate 
the FSHβ gene expression. Furthermore, GnRH stimulates Nur77 expression through 
calcineurin. Nur77 then activates the FSHβ gene expression by facilitating the 
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recruitment of co-activators, possibly together other transcription factors as a result of 

























Fig 4.10: The possible model for the roles of Nur77 and MEF2D in GnRH mediated FSHβ 
derepression. 
GnRH binding to its receptor activates PKC and leads to elevated intracellular calcium levels, which 
activates calmodulin (CaM). CaM binding activates both calcium-dependent phosphatase (calcineurin) and 
kinase (CaMKI). (A). CaMKI mediates phosphorylation and exportation of class II HDACs associated with 
the FSHβ gene promoter through MEF2D, while calcineurin, also activated by GnRH, may also allow 
MEF2D interaction with co-activators to activate the FSHβ gene expression. (B). GnRH stimulates Nur77 
expression through calcineurin. Nur77 activates the FSHβ gene expression by facilitating the recruitment of 
co-activators, possibly together with other transcription factors as a result of activation of the other GnRH 
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4.5 General conclusion and future work 
In this study some differentially expressed genes in two different gonadotrope cell lines, 
and the genes up-regulated by GnRH were identified by subtractive hybridization. Of 
these identified factors, only ubc4 and calcineurin were studied in this project. Further 
study can be done on the rest of the identified factors, which are likely to be involved in 
RNA splicing, signal transduction, cell metabolism, protein modification and microtubule 
organization. To ascertain whether they are required for GnRH signaling, various 
experiments should be carried out such as siRNA knockdown, inhibition of the gene 
product activity or its over-expression, followed by determination of the effects on GnRH 
stimulated gonadotropin gene expression.  
 
GnRH induction of ubc4 protein was found to be involved in stimulating ERα 
ubiquitylation, degradation and trans-activation of the LHβ gene. Estrogen has a crucial 
role in the estrous cycle regulating precisely the levels of circulating LH whose surge is 
crucial in instigating ovulation. The concept that the liganded ERα acts as a molecular 
switch whose activity can be modified locally at the gonadotrope by GnRH-mediated 
ubiquitylation is in keeping with this regulatory role, while adding a novel dimension to 
the molecular mechanisms regulating gonadotropin synthesis. It is the high levels of E2 at 
the end of the follicular phase that work synergistically with GnRH and leads to the pre-
ovulatory LH surge that initiates ovulation. This study showed that ubc4 mediates the 
crosstalk between E2 and GnRH signaling pathways, so ubc4 may play important roles in 
stimulating the pre-ovulatory LH surge and thus also ovulation. Knock-out of ubc4 
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specifically in the gonadotrope in transgenic mice would reveal its possible role in 
regulating ovulation. 
Previous reports have shown that calcium influx plays a key role in mediating the 
stimulatory effects of GnRH on gonadotropin genes (Johnson et al., 1997; Mulvaney and 
Roberson, 2000; Reiss et al., 1997). However, among the downstream factors mediating 
calcium effects, only calmodulin (CaM) and CaM-dependent kinase CaMKII have been 
shown to be involved in the GnRH signaling pathway (Haisenleder et al., 2003a; 
Haisenleder et al., 2003b; Roberson et al., 2005). This study revealed that the CaM-
dependent phosphatase calcineurin is also activated by GnRH, and mediates the effect of 
GnRH on the α and FSHβ subunit through activation of NFAT and Nur77. However, it is 
possible that additional calcineurin targets are involved in this process. Genetic screening 
using the immunosuppressive drug FK506 or CsA in the gonadotrope could be carried 
out to identify new gene products that closely function with calcineurin. Subsequently, 
their possible functions and mechanisms in mediating calcineurin effects could be 
examined. 
Although both reduction of ERα and an increase in calcineurin were found to be involved 
in mediating GnRH effects, no evidence from the current study suggests there is crosstalk 
between these two signaling pathways. However, previous studies in fission yeast 
indicated that there is crosstalk between calcineurin and MAP kinase pathways 
(Sugimoto et al., 1997; Sugiura et al., 1999; Sugiura et al., 1998). Since MAP kinases are 
activated in the GnRH signaling pathway, the crosstalk between calcineurin and MAP 
kinases in mediating GnRH effects is quite possible and warrants further study. 
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